

CAVELIER

ABOGADOS

www.cavelier.com
cavelier@cavelier.com

EDIFICIO SISA
CARRERA 4 No
BOGOTÁ 8, CO.

Suplente del Director de Industria y Comercio



No. 06-098637-00008-0000

Forma 2010 de 24 de 31 27 - DHP 2010 DIR. NÚM. 174282
106.11 PATENTILLYU L. 673 PASI NACIONAL
Art. 444 RESPUESTA LEGAL FOLIO 34

Señora Directora
DIRECCION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

Trámite : 011
Evento : 378
Actuación : 444

Referencia : Expediente No. 06098637
Asunto : Solicitud de patente para: **"COMPOSICIONES Y MÉTODOS PARA APLICACIÓN TÓPICA Y SUMINISTRO TRANSDERMICO DE TOXINAS BOTULINUM".**
Solicitante : **REVANCE THERAPEUTICS, INC**
Fecha de solicitud : Septiembre 29 de 2006.

1. Yo, Luz Clemencia de PAÉZ, mayor de edad, domiciliada en Bogotá, D.C., identificada con la Cédula de ciudadanía N° 35.456.344 de Usaquén, obrando como apoderada del solicitante en el asunto antes identificado, de acuerdo con la sustitución de poder a mi otorgada por el Doctor Emilio Ferrero, me refiero al Oficio No. 7217 notificado por fijación en lista del 4 de junio de 2010 y atentamente presento junto con este escrito los siguientes documentos:

- CROSLAND, R. Detection of sparse Botulinum toxin A binding sites using fluorescent latex microspheres, June 1999, vol 22, no.2, pages 113-115.
- SCHANTZ et al., properties and use of botulinum toxin and other microbial neurotoxins in medicine, microbiological reviews, march 1992, p.80-99.
- CONSOLE et al, antennapedia and HIV transactivator of transcription (TAT) protein transduction domains promote endocytosis of cel surface glycosaminoglycans, the journal of biological chemistry, 2003, vol. 276, No.37, p.35109-35114.
- SHALABY, SW. Polymers for augmenting R Botulinum vaccine efficacy, crisp data base National Institutes of Health, 2002.

A este respecto, deseamos poner de presente que las copias de los documentos arriba mencionados y que son presentadas junto con este escrito, corresponden a las copias proporcionadas al solicitante como resultado del informe de búsqueda internacional PCT, con lo que podrá realizarse un análisis absoluto de la patentabilidad de la invención correspondiente a la presente solicitud, de acuerdo con las disposiciones del artículo 46 de la Decisión 486.

Lo anterior, por cuando junto con dicho reporte solo fue proveído a mi representada el abstract del documento **SHALABY, SW**, siendo imposible obtener copia completa del mismo.

2. Puesto que se han atendido a cabalidad las peticiones hechas por su Despacho sobre la presente solicitud de patente, atentamente solicito que se continúe su tramitación.

3. **ANEXOS**

- Copia auténtica la sustitución del poder otorgado por el Doctor EMILIO FERRERO, a mi favor, para lo cual solicito me sea reconocida personería y así continuar con el trámite de este asunto en favor de la sociedad solicitante.

Señora Directora,

Luiz Clemencia de Paez

LUZ CLEMENCIA DE PAEZ
C.C. 35.456.344 de Usaquén
T.P.A. No. 23.555

COLO-15861-845-003-1
MGMMGMND-177110WPC15861
No. M-2010-177110MGM

CAVELIER

ABOGADOS

WEB SITE: www.cavelier.com
E-MAIL: cavelier@cavelier.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTÁ 8, COLOMBIA

TELEFONO: (57) (1) 347-3611
TELEFAX: (57) (1) 217-9211 (57) (1) 310-4995

Señores

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E. S. D.

Poderdante : REVANCE THERAPEUTICS, INC.

Poder conferido el : 12-12-2006

Yo, EMILIO FERRERO, obrando como apoderado principal del poderdante arriba mencionado, mediante el presente escrito sustituyo el poder a mi otorgado a la doctora LUZ CLEMENCIA DE PAEZ, identificada con cédula de ciudadanía No. 35.456.344 y Tarjeta Profesional N°23.555, con todas las facultades que me fueron conferidas.

Hago la anterior sustitución conforme al artículo 66 del Código de Procedimiento Civil.

Señora Jefe,



EMILIO FERRERO

T.P.A. N° 31.929

C.C. N° 438.019 de Usaquén


Acepto:




LUZ CLEMENCIA DE PAEZ

T.P.A. N° 23.555

C.C. No. 35.456.344 de Usaquén





Fu. L. Quintanar
Fue en casa de la abogada

NOTARIA SEXTA DE BOGOTA
RECONOCIMIENTO Y PRESENTACION PERSONAL
Bogotá, D.C.
Ante mi AMPARO QUINTANAR ARTURO,
NOTARIA SEXTA DEL CIRCULO DE
BOGOTA, D.C.
Compareció(a) *Emilio Fariña*
Guartz de Rieze
Culminó(a) exhibiendo la(s) C.C.
4388019 TP. 31929
35456344 TP. 23555
Y declaró(a) que la(s) firma(s) que se
en el presente documento es(es) la(s) suya(s) y
que el contenido del mismo es cierto.
En consecuencia se firma esta diligencia.

05/07324

Detection of Sparse Botulinum Toxin A Binding Sites Using Fluorescent Latex Microspheres

Richard D. Crosland* and Gabriela A. Canziani

Toxinology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702

Abstract

The most potent toxins known are produced by strains of *Clostridium botulinum*. To paralyze the vertebrate neuromuscular junction, the toxins bind selectively to nerve endings, translocate into the presynaptic terminal, and hydrolyze proteins of the exocytotic apparatus, thus inhibiting the release of acetylcholine. Our goal was to develop a convenient, reliable technique to detect specific binding of botulinum toxin A to its targets, a technique that could be easily modified to detect the binding sites of other ligands as well. Our method utilized fluorescent latex microspheres and is theoretically capable of detecting a single binding site at the light microscopic level.

Nonspecific binding sites on 7- μ m thick sections of unfixed, cryosectioned mouse diaphragm were first blocked with 20% goat serum in phosphate-buffered saline (GS/PBS). We incubated the diaphragm for 1 hr at 22° with various concentrations of botulinum toxin A in GS/PBS, followed by incubation with rabbit anti-botulinum toxin A antiserum, biotin-labeled goat anti-rabbit antibody, and finally avidin-labeled, 0.03 μ m diameter, fluorescent latex microspheres.

As expected, binding was localized to the area of the neuromuscular junction. Binding was also observed in association with axons innervating some junctions. We could detect binding on diaphragms that were exposed to as little as 10 pM botulinum toxin A, which is in the low range of effective in vitro doses that block neuromuscular transmission. This is a convenient, sensitive, and specific technique for detecting botulinum toxin A binding sites that is easily modifiable for the detection of binding sites of other ligands as well. (*The J Histotechnol* 22:113, 1999)

Key words: diaphragm, immunohistochemistry, labeling, light microscopy, mouse, neuromuscular junction, synapse

Introduction

The neurotoxins produced by strains of *Clostridium botulinum* are among the most toxic substances known. It has been estimated that, at most, 100–1000 molecules of botulinum toxin A are required to poison a presynaptic terminal, suggesting that there are relatively few receptors for the toxins (1–3). The toxins bind to the presynaptic membrane, are internalized, and proteolyze components of the release apparatus, thereby blocking release of acetylcholine. Their in vivo sites of action are limited to peripheral cholinergic terminals, and the proximate cause of death is respiratory failure.

There have been few histological studies of the binding of botulinum toxins to their target tissues (1,4–9). One reason for this is the low density of toxin binding sites, which necessitates a detection system with a high signal-to-noise ratio (1). To date this has usually meant autoradiography with radiolabeled toxin and fixed tissue. This technique suffers from several shortcomings, however. Radiolabeling botulinum toxin to a sufficiently high specific radioactivity while retaining biological activity is not a trivial undertaking. With such a potent toxin, furthermore, there is the possibility that a small percent of unlabeled toxin will bind and be active whereas the radiolabeled toxin will not bind (or bind nonspecifically) and be inactive, and the radiolabeled toxin is what is being measured. Inactivation of a substantial percentage of toxin by labeling may not be readily discernible because botulinum toxin activity is assayed by mouse lethality, which is not very precise. Another pitfall with the binding protocols used to date has been the tendency to use unphysiologically high doses of labeled toxin to increase the signal. Finally, the use of fixed tissue can cause artifacts. Our goal was to avoid some of the problems described and to detect botulinum toxin binding sites easily by light microscopy, with as little alteration as possible to the sites or the toxin. We also wished to develop a general technique that could be easily modified to detect the binding sites of other ligands.

We developed a method based on antibody detection vi-

* Address reprint requests to Dr. Crosland

stained with fluorescent latex microspheres. Each microsphere contains 100,000 fluorescent molecules, rendering it easily discernible with a fluorescence microscope. A microsphere can be attached to a binding site through a chain of binding site-botulinum toxin-primary antibody-secondary antibody-microsphere, thus allowing detection of a binding site.

Materials and Methods

Materials

We purchased botulinum toxin A from List Biologicals (Campbell, CA) and assayed it with a mouse bioassay. We purchased biotin-labeled goat anti-rabbit antibody from Kirkegaard & Perry (Gaithersburg, MD), and fluorescent latex microspheres (Transfluospheres[®]) that were avidin-labeled and 0.030 μm in diameter from Molecular Probes (Eugene, OR). Neutralizing rabbit anti-botulinum toxin A antiserum was produced at this institution. Naive goat serum came from Sigma Chemical Co (St Louis, MO). Frosted, treated microscope slides were purchased from Fisher Scientific (Pittsburgh, PA), specimen embedding medium from Tissue-Tek (Elkhart, IN), and Aqua-Mount from Lerner Laboratories (Pittsburgh, PA).

Methods

Male, BALB/C, 20–25 gm mice (Harlan Sprague-Dawley, Frederick, MD) were maintained on a 12 hr light-dark (1800–0600) cycle, and allowed free access to food and water. Their care and use were in compliance with the Animal Welfare Act (USA) and the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (USA). After mice were killed by cervical dislocation, we removed the diaphragm under saline, cut it into hemidiaphragms, froze them on dry ice for 15–20 min in specimen embedding medium, and stored them at -70° until sectioned. We cut the frozen hemidiaphragms into 7- μm thick sections on a cryostat at -25° . The sections were picked up onto treated slides, dried in air at room temperature, numbered, and stored in a desiccator until used, usually the next day.

All of the following procedures were performed in a humid chamber at room temperature with the slides resting horizontally. We wetted sections with 0.5 ml of 20% goat serum in phosphate-buffered saline (GS/PBS) for 20 min. We then added botulinum toxin A in GS/PBS to each section and incubated it for 1 hr, followed by 5 washes (immersion) with PBS. Sections were incubated for 2 hr with rabbit anti-botulinum toxin A antiserum (1 $\rightarrow$ 10) in GS/PBS, followed by another 5 washings in PBS and a 30 min incubation in GS/PBS. We added biotin-labeled goat anti-rabbit antibody (1 $\rightarrow$ 500) in GS/PBS and incubated the sections for 1 hr, followed by 5 washes with 3 $\times$ PBS. The sections were incubated with avidin-labeled fluoromicrospheres (10^8 particles/ml in GS/PBS + 0.005% Tween 20) for 1 hr and then washed 5 times with PBS. We added 1 drop of Aqua-Mount and a coverslip. The sections were observed under a fluorescence microscope with a fluorescein filter set.

Results

We used our method of botulinum toxin-primary antibody-secondary antibody-microsphere to label sparse botu-

linum toxin A binding sites of the presynaptic elements of neuromuscular junctions. On sections of diaphragm incubated with 1 nM botulinum toxin A (Figure 1) we observed microspheres that were configured in a way that was consistent with an association with the presynaptic elements of the neuromuscular junction, the proximal portion of the axon of the presynaptic neuron, and, in many cases, distal portions of the axon of the presynaptic neuron (10). The labeled areas were always associated with myofibrils and were arranged in a band along the medial aspect of the muscle. In addition, the dimensions of the labeled areas were comparable to the reported dimensions of the endplate region (11). Furthermore, the size, number, and distribution of labeled areas were comparable to that observed when we stained sections for cholinesterase or labeled them with rhodamine-conjugated α -bungarotoxin (not shown). Labeling with microspheres was very specific because they were limited to presynaptic elements of neuromuscular junctions and their innervating neurons. No other structures were labeled, and there were very few background microspheres. Incubation of diaphragm with 10 pM botulinum toxin A resulted in localization of microspheres to endplate regions, but there were fewer numbers of microspheres than observed after incubation with 1 nM botulinum toxin A. We observed no labeling when botulinum toxin A or rabbit anti-botulinum toxin A antiserum was omitted.




Figure 1. Fluorescence photomicrograph showing distribution of microspheres on mouse diaphragm after incubation with 1 nM botulinum toxin A followed by antibodies and microspheres. Muscle fibers autofluoresce green whereas microspheres are yellow. Arrows indicate endplates. The motor endplate in the center of the field shows labeling of axon leading to it. Bar = 25 μm .

Discussion

Our goal was to develop a simple technique to detect sparse botulinum toxin binding sites at the light microscopic level using unlabeled toxin and unfixed tissue. We also wanted the technique to be easily modifiable to enable the detection of binding sites of other ligands. We attained our goal with an indirect immunohistological technique that linked fluorescently labeled latex microspheres to binding sites through a chain of binding site-botulinum toxin-primary antibody-secondary antibody-microsphere.

When we incubated diaphragm sections with a moderate (1 nM) concentration of botulinum toxin A, we observed microspheres on the muscle in a pattern that was consistent with toxin binding to presynaptic elements of neuromuscular junctions and the terminal portion of motor neurons. This was expected as botulinum toxin A is a marker for the presynaptic element of the neuromuscular junction. We observed a similar but less robust pattern of labeling after incubating sections with 10 pM toxin, which is in the low range of effective in vitro doses that block neuromuscular transmission (12). Our observations were in concordance with those of Black and Dolly and Dolly et al (1,6). They showed with electron microscopic autoradiography that 15 nM [¹²⁵I]botulinum toxin A labeled only the presynaptic elements of neuromuscular junctions of mouse diaphragm and that the labeling was present on the plasma membrane, within the nerve terminal, and within the axoplasm of the nerve trunk. They also stated that they observed saturation of labeling with 200 pM toxin by light microscopic autoradiography. Thus, in all aspects, the 2 very different labeling techniques revealed similar distributions of botulinum toxin A binding sites. Our method, in addition, showed microspheres associated with more distal portions of the axons of presynaptic neurons, probably because of botulinum toxin A binding to components transported along the axon.

We successfully developed a simple technique to detect sparse botulinum toxin binding sites by light microscopy using unlabeled toxin and unfixed tissue. We linked fluorescent latex microspheres to binding sites through a chain of binding site-botulinum toxin-primary antibody-secondary antibody-microsphere. Although we do not claim to have done so, this technique can theoretically detect a single binding site. In addition, through a similar chain of antibodies, through a biotinylated ligand, or by attaching a ligand of interest directly to the microspheres our technique could easily be modified to locate the binding sites of other ligands.

Acknowledgments

We thank Dr. Cameron Gundersen for helpful discussions and Dr. Peter Vogel for help with the photography. A preliminary report of this work was presented as the 25th Annual Meeting of the Society for Neuroscience, San Diego, CA, November 1995.

References

1. Black JD, Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. *J Cell Biol* 103: 521-534, 1986
2. Hanig JP, Lamanna C: Toxicity of botulinum toxin: a stoichiometric model for the locus of its extraordinary potency and persistence at the neuromuscular junction. *J Theor Biol* 77: 107-113, 1979
3. Simpson LL: The origin, structure, and pharmacological activity of botulinum toxin. *Pharmacol Rev* 33:155-188, 1988
4. Black JD, Dolly JO: Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. *J Cell Biol* 103:535-544, 1986
5. Dolly JO, Williams RS, Black JD et al.: Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain membranes. *Toxicon* 20:141-148, 1982
6. Dolly JO, Black J, Williams RS, Melling J: Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. *Nature* 307:457-460, 1984
7. Hirokawa N, Kitamura M: Localization of radioactive 125I-labelled botulinus toxin at the neuromuscular junction of mouse diaphragm. *Naunyn Schmiedeberg's Arch Pharmacol* 287:107-110, 1975
8. Zacks SI, Metzger JF, Smith CW, Blumberg JM: Localization of ferritin-labeled botulinus toxin in the neuromuscular junction of the mouse. *J Neuropath Exp Neurol* 21:610-633, 1962
9. Zacks SI, Rhoades MV, Sheff MF: The localization of botulinum A toxin in the mouse. *Exp Molec Path* 9:77-83, 1968
10. Couteaux R: Localization of cholinesterases at neuromuscular junctions. *Int Rev Cytol* 4:335-375, 1955
11. Salpeter MM, Eldefrawi ME: Sizes of end plate compartments, densities of acetylcholine receptor and other quantitative aspects of neuromuscular transmission. *J Histochem Cytochem* 21:769-778, 1973
12. Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. *J Pharmacol Expt Therap* 212:16-21, 1980

6



Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine

EDWARD J. SCHANTZ¹ AND ERIC A. JOHNSON^{1,2*}

Departments of Food Microbiology and Toxicology¹ and of Bacteriology,² Food Research Institute, University of Wisconsin, 1925 Willow Drive, Madison, Wisconsin 53706

INTRODUCTION.....	80
MICROBIAL NEUROTOXINS THAT BLOCK NEUROTRANSMITTER RELEASE.....	81
Properties of Botulinum Toxin Type A Relevant to Its Use in Medicine.....	81
Developments leading to the use of the toxin for human treatment.....	81
Special considerations on the preparation and maintenance of botulinum toxin type A for human treatment.....	81
Mechanisms of action of botulinum toxin.....	81
Preparation and properties of botulinum toxin type A for clinical use.....	82
Therapeutic applications of botulinum toxin.....	83
Side effects of botulinum toxin.....	85
Changes in muscle tissue following botulinum toxin type A injections.....	85
Immunity to botulinum toxin.....	85
Properties and Uses of Serotypes of Botulinum Toxin Other than Type A.....	86
Botulism in humans.....	86
Toxin production by the various serotypes of <i>C. botulinum</i>	86
Significance of complexes on toxin quality.....	87
Biochemical and genetic properties of the neurotoxin component.....	87
Structure and properties of nontoxic proteins of the toxin complex.....	88
New findings in the mechanisms of action of the different types of botulinum toxins.....	89
Clinical use of pure neurotoxin compared with toxin complexes.....	89
Tetanus Toxin.....	89
Crystalline structure.....	90
Biosynthesis and activation of tetanus toxin.....	90
Large-scale production of tetanus toxin.....	90
Genetics of tetanus toxin.....	90
Pharmacological and medical applications of tetanus toxin.....	91
MICROBIAL NEUROTOXINS THAT ALTER VOLTAGE-GATED SODIUM CHANNELS.....	92
CONCLUSIONS.....	93
ACKNOWLEDGMENTS.....	93
REFERENCES.....	93

INTRODUCTION

The eminent physiologist Claude Bernard wrote in his classic work entitled *Experimental Science* (8), "Poisons can be employed as a means for the destruction of life or as agents for the treatment of the sick." He went on to explain how certain toxins and poisons were valuable tools for analyses of the most delicate phenomena of living structures. Although several toxic substances of plant and animal origin were used in medical practice during his time, in recent years a great multitude of poisonous substances from plants, animals, and microorganisms are now finding use in studies on animal physiology and some are used medicinally in humans.

In December 1989 the U.S. Food and Drug Administration licensed botulinum toxin type A as an orphan drug for the treatment of the human muscle disorders strabismus, hemifacial spasm, and blepharospasm in patients 12 years of age and older, by direct injection of the toxin into the hyperactive muscle. Botulinum toxin is also being used experimen-

tally for the treatment of a number of other dystonias and movement disorders (25, 98, 191). The use of the toxin for human treatment came about over 20 years ago through the collaborative work of Alan B. Scott and E. J. Schantz. The treatment of neurological disorders with botulinum toxin type A has opened a new field of investigation on the application of the toxin to nerve and muscle tissue in the human body.

Various microbial neurotoxins are being used to understand the physiology of the nervous system and may have potential value in the treatment of certain types of muscular disorders through modification of nervous stimulation of muscle activity. Well-characterized microbial neurotoxins for this purpose include the neurotoxic proteins from *Clostridium botulinum* and *Clostridium tetani* and the low-molecular-weight neurotoxins saxitoxin and tetrodotoxin, from certain species of dinoflagellates and bacteria (Table 1). These toxins affect muscular activity by their direct action on the nervous system; for example, botulinum and tetanus toxins affect activity by a presynaptic block of the release of neurotransmitters, and saxitoxin and tetrodotoxin do so by altering the action potential at the voltage-gated sodium channels of neurons. These toxins differ from many other

* Corresponding author.

TABLE 1. Approximate relative toxicities of microbial neurotoxins

Toxin	Minimum lethal dose in mice (µg/kg)	Mol wt
Botulinum toxin, type A, crystalline	0.00003	900,000
Tetanus toxin, crystalline	0.0001	150,000
Saxitoxin (free base)	9	299
Tetrodotoxins	8-20	319

microbial toxins such as diphtheria and cholera enterotoxins in that they exhibit relatively little cytolytic or cytotoxic activity. This review describes properties of presently known neurotoxins that are obtained from microorganisms and that, through their physiological action, may be valuable in medicine and pharmacology, particularly botulinum toxin type A, the only toxin which is presently being used for the treatment and relief of several human dystonias. It also points out the need for research on methods for culturing, purification, genetic expression, and preservation of these toxins applicable to their use for human treatment.

MICROBIAL NEUROTOXINS THAT BLOCK NEUROTRANSMITTER RELEASE

Properties of Botulinum Toxin Type A Relevant to Its Use in Medicine

Developments leading to the use of the toxin for human treatment. Botulinum neurotoxins are produced by certain strains of the bacterial species *C. botulinum*, *Clostridium butyricum*, *Clostridium baratii*, and *Clostridium argentinense* (86). The toxins are classified into seven serotypes, A through G, on the basis of their immunological properties. The botulinum neurotoxins comprise a family of pharmacologically similar toxins that block acetylcholine release from peripheral nerves and cause a flaccid paralysis. All of the serotypes of toxin can poison humans and other animals, but type A has caused the severest illness and many deaths from food-borne botulism and is the best-characterized botulinum toxin. Crystalline type A toxin is the serotype that is currently being used in therapeutic applications. The following sections describe the basic properties of botulinum toxin type A and the development of the toxin as a drug.

Investigations into the use of botulinum toxin type A for the treatment of hyperactive muscle disorders originated over 20 years ago through a fortunate set of circumstances and the ingenuity of Alan B. Scott, a surgeon at the Smith-Kettlewell Eye Research Institute in San Francisco. He contacted one of us (E.J.S.) regarding the availability of a toxic substance that might be injected into a hyperactive muscle and thus serve as an alternative to surgery for the treatment of strabismus, a condition in which the eyes are out of alignment. In my research on microbial toxins I had on hand highly purified crystalline type A botulinum toxin, produced by *C. botulinum*, and saxitoxin, the potent poison produced by the dinoflagellate *Gonyaulax catenella*. The mechanisms of action of these toxins had been known for many years (29, 33, 63, 103), and their possible use in the treatment of a hyperactive muscle was apparent but had never been tested. No record of such use in animals or humans was available. Both botulinum toxin and saxitoxin cause flaccid paralysis of skeletal muscle as a result of action

on the nervous system. Botulinum toxin type A appeared to be the toxin of choice for human treatment on the basis of animal studies and accidental cases of human food poisoning in which the paralytic action on survivors lasted for many weeks whereas recovery from saxitoxin poisoning took only a few days for survivors. We therefore began our collaboration on this work by using botulinum toxin experimentally on rhesus monkeys, in which Dr. Scott surgically produced a condition similar to strabismus. With the properly determined dose of botulinum toxin injected into the more active muscle, proper alignment of the eyes was achieved.

After 10 or more years of successful experiments on monkeys, the FDA granted Dr. Scott permission to treat strabismus in human volunteers. Strabismus in humans is a disorder of vision due to turning of one or both eyes from the normal position for binocular vision and is caused by hyperactivity of one or more muscles controlling eye position. This condition in humans usually is corrected by surgery, which involves cutting away a sufficient portion of the hyperactive muscle to allow the eye to assume its normal position. Successful human treatment with the toxin involved injecting measured amounts of the toxin, under carefully controlled conditions using electromyography, directly into the hyperactive muscle pulling the eye out of alignment. Injection of botulinum toxin weakened the overactive muscle, enabling compensation by the weaker one and resulting in permanent eye alignment after a period of temporary paralysis (192). The clinical work was first reported by Scott in the 1980s (188, 189), and the properties of the toxin in relation to its use in medical treatment was reported by Schantz and Scott in 1981 (180).

Special considerations on the preparation and maintenance of botulinum toxin type A for human treatment. Although the original toxin on hand and that prepared for the monkeys was sufficient, the toxin to be used for the human trials had to be prepared under more specific conditions that would, from best judgment, meet approval by the FDA. Botulinum toxin is the first microbial protein to be used via injection for the treatment of human disease. There was no precedent for the use of a microbial toxin in this manner, and protocols for this work had to be implemented. The important considerations regarding the toxin were its purity and dose on injection. The production by culturing and the purification had to be carried out so that the toxin was not exposed to any substance that might contaminate the final product in trace amounts and cause undue reactions in the patient. These restrictions required culturing in simplified medium without the use of animal meat products and purification by procedures not involving synthetic solvents or resins. Another concern was the problem of long-term stability of the toxin so that a supply was always available. Dilution of the toxin from milligram quantities to a solution containing nanograms per milliliter presented a problem because of the rapid loss of specific toxicity on such great dilution. Toxin can be diluted in pyrogen-free water or saline if used immediately for treatment, but stabilization of the toxin for longer periods requires the presence of another protein such as gelatin or albumin (173, 177). Although the commercial botulinum type A product is prepared in the presence of human serum albumin, the use of human serum albumin presents potential problems in that certain stable viral agents carried through from donors could contaminate the toxin. These and other concerns about the preparation and use of the toxin for human treatment are reviewed and discussed in the following sections.

Mechanisms of action of botulinum toxin. The primary

structure of the neurotoxin is such that the resulting shape (secondary and tertiary structures) causes a highly specific binding and block of acetylcholine release at myoneuronal junctions. Botulinum toxin is toxic to all vertebrates through weakening of skeletal muscle, and death may come about through paralysis of the muscles of respiration. Van Ermen-gen (226) considered that the toxin acted on the central nervous system, but it was later shown that the action is peripheral rather than central (50, 60). Most early studies on the mechanism of action of botulinum toxin were carried out with type A crystalline toxin (29, 33, 79). Botulinum toxin blocks cholinergic transmission at all cholinergic synapses in the peripheral nervous system, but conduction along axons is not affected (79). The chemical denervation lasts for several months, and recovery of neurotransmission and muscle activity requires sprouting of new nerve endings and functional connections at motor end plates. The biochemical mechanisms of botulinum toxin in skeletal neuromuscular preparations, brain synaptosomes, chromaffin cell cultures, spinal cord cell cultures, and *Torpedo* and *Aplysia* preparations have been reviewed within the last 10 years (45, 81, 137, 158, 168, 200).

Preparation and properties of botulinum toxin type A for clinical use. The Food Research Institute, University of Wisconsin, has been involved in the production of crystalline toxin pertaining to food safety for many years, and small amounts of this toxin were used for the work on monkeys. However, the toxin that was to be used for human treatment by injection required special considerations, and preparation and purity of the toxin became essential (180). The type A toxin Hall strain was chosen for production of toxin because it consistently produced high levels of toxin (1 to 4 million mouse 50% lethal doses (MLD₅₀) per ml of culture broth). It was originally obtained from J. H. Mueller of Harvard University (118), and was developed at Fort Detrick, Md., by screening for high toxin production. Toxin is produced in a nutritive medium consisting of a casein digest, yeast extract, and dextrose at pH 7.3. Following inoculation, growth is usually complete in 24 to 36 h, at which time cells undergo lysis. Complete lysis and clearing of the culture take 2 to 3 days. The toxin is liberated during lysis and is activated by proteases present in the culture broth that convert a poorly active protoxin to the highly potent toxin.

The first successful attempt at purification of type A toxin from culture broths was accomplished by Snipe and Sommer (203) at the Hooper Foundation at the University of California in 1928, when they showed that 90% of the crude toxin could be precipitated from the spent culture fluid by the addition of acid to pH 3.5. About 20 years later, Lamanna et al. (113), starting with the precipitate, obtained the toxin in crystalline form, and then Duff et al. (59) improved the method; the improved method is the basis for the present procedure for purification. The purification of botulinum toxin type A in our laboratory for human use was designed to be carried out by the simplest procedures and avoided exposure to substances such as added enzymes or columns of synthetic resins, used in some methods, that could contaminate the preparation and be carried into the final injected preparations. It is briefly described as follows. The type A toxin in the spent broth was first precipitated by adjustment to pH 3.5 with acid; 90% of the toxin was recovered in the precipitate. The precipitate was washed with water, and the toxin was extracted with 1 M salt solution at pH 6.5 and reprecipitated with acid at pH 3.7. The toxin was extracted from this precipitate with 0.05 M sodium phosphate buffer at pH 6.8, precipitated in 15% ethanol at -5°C, redissolved in

phosphate buffer, and crystallized in 0.9 M ammonium sulfate. This simplified procedure yields, for example, 60 to 70 mg of small, white, needle-shaped crystals (0.1 to 0.2 mm in length) from a 12-liter culture (15 to 17% recovery). Recrystallization under the same conditions yields 20 to 25 mg of crystalline toxin.

The crystalline type A toxin contains 16.2% nitrogen and, as far as is known, is composed only of biologically active amino acids (32, 207) for both the neurotoxin and the nontoxic proteins. The isoelectric point of the crystalline type A toxin is pH 5.6. Under slightly acidic conditions, pH 3.5 to 6.8, the neurotoxic component of 150,000 *M*_r is bound noncovalently to the nontoxic proteins in such a manner as to preserve or help stabilize the second and tertiary structures upon which toxicity is dependent. Under slightly alkaline conditions (>pH 7.1) and in the blood and tissues of animals and humans, the neurotoxin is released from the toxin complex. RNA is also associated with the toxin complex but has no known role in activity or stability.

The molecular weight of crystalline toxin was initially shown to be 900,000 *M*_r on analysis in the ultracentrifuge at pH 3.8 to 4.4 (161, 173, 181, 229). Putnam et al. (161) showed that on electrophoresis, the crystalline toxin moved as a single substance with a molecular weight of 900,000. Lamanna et al. (115) discovered that purified type A toxin could be separated into nontoxic and toxic components, when they found that a nontoxic component precipitated erythrocytes leaving the toxin in solution. Wagman and Bateman (229) also showed that the toxin moved in the ultracentrifuge as a single substance with a sedimentation coefficient of 19S at pH 5.6, but at pH 7.3 the toxin component (neurotoxin) dissociated and moved as a much smaller molecule (7S). Later DasGupta and Boroff (46) showed that at alkaline pH the neurotoxin could be separated from the nontoxic proteins by column chromatography.

On diffusion in agar gel at pH 4.2 the crystalline toxin moves as a single substance with a coefficient (*D*) of ca. $2 \times 10^{-7} \text{ cm}^2 \text{ s}^{-1}$ (161, 178). However, at pH 7.3, near to the pH at which the neurotoxin and nontoxic components dissociate, the diffusion rate of the neurotoxin increased to ca. $8 \times 10^{-7} \text{ cm}^2 \text{ s}^{-1}$, much higher than the rate expected for a globular protein molecule of 150,000 *M*_r (178). Diffusion depends to a great extent on the shape of the molecule, and the toxin may take on a threadlike structure that would diffuse faster than a globular structure.

The biological activity (toxicity) of the toxin, like many other biologically active proteins, is due to the spatial or conformational structure of the neurotoxin molecule (173, 182). The nontoxic proteins bound to the neurotoxin apparently play an important role in maintaining the toxic shape of the neurotoxin. Careful handling of purified toxin is therefore important for maintenance of stability. Botulinum toxin type A is readily denatured by heat at temperatures above 40°C, particularly at alkaline pH. Solutions of the toxin lose toxicity when bubbles form at the air/liquid interface causing stretching and pulling of the neurotoxin out of its toxic shape (173). This denaturation also takes place in an atmosphere of nitrogen or carbon dioxide. Dilution to extremely low concentrations (nanograms per milliliter) also tends to decrease the stability of the neurotoxin, but this can be prevented by diluting with a buffered solution (at pH 6.8 or below) containing another protein such as gelatin and certain albumins such as bovine or human serum albumin. When the pH is raised above 7.3, the neurotoxin is liberated, which is very labile. Because of its lability the neurotoxin is not practical for medical applications.

Crystalline botulinum toxin type A was the first microbial protein of this complexity to be considered an injectable substance by the FDA, and it was necessary to set down specifications for toxin quality. The following properties of the crystalline toxin obtained from many batches were found to be of the highest-quality toxin and were used for evaluation of batch 79-11, which was used in initial studies in humans and later licensed by the FDA: (i) a maximum absorbance at 278 nm when dissolved in 0.05 M sodium phosphate buffer at pH 6.8, (ii) an A_{260}/A_{278} ratio of 0.6 or less, (iii) a specific toxicity for mice of $3 \times 10^7 \pm 20\%$ MLD₅₀ per mg, and (iv) an extinction coefficient (absorbance) of 1.65 for 1 mg of toxin per ml in a 1-cm light path.

The purity of the crystalline toxin cannot be defined strictly in terms of percent purity because of small amounts of undefined material absorbing at 260 nm, most probably nucleic acid material, which associates with the toxin during culturing and is carried through the purification and crystallization procedures. This property is peculiar to certain crystalline proteins, in contrast to the crystallization of other simpler organic substances. We have based the quality of the toxin on obtaining as low an A_{260}/A_{278} ratio as possible, near to 0.55. Toxin from the first crystallization has a ratio close to 0.6, and on the second crystallization it should be reduced to about 0.55, which is considered representative of high-quality toxin. A third crystallization may reduce the ratio slightly but at a cost of yield, because only one-third to one-half of the toxin is recovered on each crystallization. Other crystalline proteins such as human and bovine serum albumins have absorbance ratios close to 0.5 (232). If it is assumed that the absorbing material at 260 nm is nucleic acid with an extinction of 20 per mg (12 times that of the toxin), the proportion of nucleic acid in a preparation with a ratio of 0.6 would be less than 0.1%.

Another test of purity and consistency for each batch of type A toxin is the banding pattern on solution electrophoresis and gel electrophoresis with crystalline toxin and reduced crystalline toxin. At or below the isoelectric point of 5.6, the toxin moves as a single homogeneous substance, of 900,000 M_r . Toxin reduced with sulfhydryl reagents shows the distribution after electrophoresis of the nontoxic components along with the neurotoxin subunits of 100,000 and 50,000 M_r . Electrophoresis carried out on several batches of crystalline toxin showed that the toxin is judged very similar for each batch (101).

The specific toxicity of a high-quality preparation of crystalline toxin should be 3×10^7 MLD₅₀ ($\pm 20\%$) per mg. The number of milligrams for this determination is based on the A_{278} , using the extinction of 1.65 to convert to milligrams of toxin ($A_{278}/1.65 =$ milligrams of toxin ($\pm 3\%$)) (207). Because the immunological properties of type A toxin are independent of its toxic properties, the only means of evaluating the potency or acetylcholine-blocking power of the toxin is an animal assay (176). The mouse assay for toxicity determination may vary depending on the species of mice, their condition, and the conditions under which the assay is carried out. To minimize the variability, it is recommended that the mouse assay be carried out on any preparation used for human treatment with the use of a reference standard of type A toxin as described by Schantz and Kauter (177). There is no known chemical, physical, biological, or immunological test available that can replace the mouse test for toxicity evaluation.

An important factor in the medical use of botulinum toxin is a method of storage for retention of toxicity. The crystalline toxin formerly provided for reference in food assays was

dissolved and stored in 0.05 M sodium acetate buffer (pH 4.2) at 4°C (177), in which it retained toxicity for 1 to 2 years before a significant loss (20%) could be detected by mouse assay. The difficulty with storing the toxin in acetate buffer is that freezing causes complete detoxification and reliance on storage at 4°C without danger of freezing is not practical under certain circumstances. However, we have found that the most satisfactory method of storage is to leave the crystalline toxin at 4°C in the mother liquor of the second crystallization, in which toxicity was retained for 10 or more years. Retaining stability is important because it makes available a bulk supply of toxin to draw from over an extended period. When the FDA approved experimental trials on human volunteers, a large batch of crystalline toxin was prepared in November 1979 (designated 79-11) expressly for the human trials; 100 mg was supplied to Alan Scott and 50 mg was retained in storage at the Food Research Institute. This batch has been the sole source of botulinum toxin type A accepted by the FDA for human treatment and has been used by many physicians throughout the United States and some foreign countries. However, some loss in toxicity has occurred in batch 79-11, and we recommend that fresher batches of toxin periodically be prepared to avoid detrimental changes that may occur on aging. Crystalline type A toxin prepared in our laboratory does not appear to differ in potency or clinical efficacy from type A toxin prepared in England by using anion-exchange chromatography and RNase treatment (133, 222). However, we do not recommend the use of methods of purification involving enzymes, various exchangers, or synthetic solvents because of the chance of contamination.

Preparation of the toxin for dispensing as a drug and compatible for injection into muscle required (i) dilution in a suitable medium for stability of toxicity, (ii) filtration for sterility, and (iii) drying. Diluting a solution of botulinum toxin type A from a concentration of 1 or 2 mg/ml to nanogram concentrations causes detoxification unless another protein is added for protection. Gelatin at 2 to 3 mg/ml is generally used at pH 6.2 in the standard procedure for the mouse assay for toxin in foods (177). Bovine serum albumin has been used at 2 to 3 mg/ml in acetate buffer at pH 4.2 for good stability (177), and human serum albumin was adopted for medical use. Filtration in the presence of additional protein can be carried out successfully to remove bacterial contamination without loss of toxicity. However, drying, which would have many advantages in long-term stability, under the conditions with human serum albumin at pH 7.3 resulted in a substantial loss (50 to 90%) of toxicity. This loss of toxicity is a very important consideration because of the possibility that the inactivated toxin will form a toxoid and immunize the patient against the toxin on continued use. Various methods of drying, particularly lyophilization, resulted in such losses. Experience with the toxin has proved that stability of toxicity is dependent on low pH (<7), but such low pHs are not compatible with injections into muscle tissue. A significant problem is the development of a medium and conditions to overcome the losses on drying, and research for this purpose is being carried out in our laboratory.

Therapeutic applications of botulinum toxin. Clinical studies have indicated that toxin injections can provide profound symptomatic relief for humans suffering from a wide variety of disorders characterized by involuntary movements of muscle groups (Table 2), particularly those involved in focal or segmental dystonias (25, 64, 92, 127). In 1911, Oppenheim (151) introduced the term "dystonia musculorum defor-

TABLE 2. Focal dystonias and involuntary movement disorders successfully treated with botulinum toxin type A*

Condition	Symptoms of disease
Strabismus.....	Crossed eyes
Blepharospasm.....	Spasmodic eye closure
Hemifacial spasm.....	Facial twitching and spasms
Eyelid disorders.....	Inward turning of eyelid
Spasmodic torticollis.....	Abnormal movements or twisting of the neck and head
Oromandibular and lingual dystonia.....	Sustained mouth closure or lingual muscle contractions
Focal dystonias of the hand.....	Writer's cramp, musician's cramp, hand and arm muscle spasms
Spasmodic dysphonia.....	Uncontrolled vocal fold spasms
Other voice disorders.....	Vocal tremor, stuttering
Neurogenic bladder.....	Abnormal urinary control; results from spinal cord injury
Anismus.....	Uncontrollable anal sphincter contraction
Limb spasticity.....	Occurs following stroke and other neurological disorders including cerebral palsy

* Listed approximately in decreasing order of numbers of patients treated (25, 98, 179, 191).

mans" to describe children who had movement disorders such as twisted postures, bizarre walking with bending and twisting of the torso, and severe muscle spasms. Oppenheim pointed out that progression of symptoms often resulted in fixed postural deformities. Dystonia is currently defined as "a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures" (64, 127). Dystonia can affect all regions of the body (127). Many patients with dystonias have been diagnosed as experiencing psychological stress and referred for psychological therapy (64), but were later found to suffer from specific neurological diseases (64, 127). Adult onset of focal or segmental dystonias (which affect only one or a few muscle groups) are more common than generalized dystonias (64, 127). A study in Minnesota estimated the prevalence of various dystonias to be 391 per million population (147). Focal dystonias may spread and lead to generalized dystonias, in which several muscle groups are involved. Focal dystonias progressed to generalized conditions in nearly 60% of affected children (onset before age 13) and in about 3% of adults (onset after age 20) (127).

Crystalline botulinum toxin has had great benefit in the treatment of involuntary muscle conditions, and injection of toxin is now considered the most effective treatment for a variety of focal dystonias (25, 98, 191). On injection the toxin acts directly or indirectly to alleviate conditions that result from muscle hyperactivity. Direct paralysis of target muscles is desired for certain indications including blepharospasm, torticollis, and other focal dystonias. Depending on the syndrome, toxin injection generally relieves undesired muscle movement for a few months, after which the abnormal movement returns and repeated injections are required. Paralysis of certain muscle groups can also lead to secondary desired effects (191). For instance, paralysis of a hyperactive muscle enables compensation by a weaker muscle, as in treatment of strabismus and certain limb muscle spasmodic disorders. In these conditions, the balancing of agonist and antagonistic muscle systems is the desired effect (191).

Strabismus was the first syndrome for which botulinum toxin therapy was introduced as an alternative to surgery

(188, 189, 192). Botulinum toxin is usually injected into the recti muscles with a Teflon-coated needle and electromyographic guidance to ensure accurate placement in the muscle; this is usually an office procedure. The toxin evokes a temporary denervation and muscle weakening, allowing the globe to return to normal alignment. Although botulinum toxin will not replace conventional surgical treatment, it has proved to be a useful adjunct to surgery in certain cases (189, 191).

Botulinum toxin is being used primarily for the correction of focal dystonias and other regional movement disorders. One syndrome approved for treatment is essential blepharospasm, in which persons suffer from involuntary eyelid closure. Blepharospasm is often accompanied by involuntary movements of head and neck muscles, a condition known as Meige syndrome (98). Meige syndrome manifests as uncontrolled blinking (blepharospasm) plus involuntary facial grimacing, frowning, facial contortions, spasmodic speech, and neck pulling (spasmodic torticollis) (24, 25). The age of onset of blepharospasm is often 50 to 70 years, and the syndrome may progress to other muscle regions. Injections of botulinum toxin type A into the orbicularis oculi muscle has given clinically significant benefit in 70 to 90% of more than 8,000 treatments (98). In most patients, the latency period from injection to onset of improvement was 2 to 5 days and relief persisted for an average of 3.5 months. The average dose was ca. 20 U (191). In some treatments, toxin diffused to neighboring muscles and caused temporary ptosis. Some patients have received repeated injections for 7 years or more, and no adverse long-term effects have been observed.

Hemifacial spasm is an often disfiguring syndrome characterized by involuntary movement of facial muscles controlled by the seventh facial nerve. Patients often find the movements disfiguring and socially and functionally incapacitating (25). Treatments with neuroleptic medications have been entirely ineffective. Injection of botulinum toxin (generally 10 to 20 U) has relieved hemifacial spasm in more than 90% of the patients treated. Most patients experience relief for 3 to 4 months, after which repeated injections have provided long-term relief in most individuals.

Spasmodic torticollis (cervical dystonia) is a dystonia affecting neck muscles and causing the head to involuntarily deviate in any direction (25, 75, 98, 208). It is among the most common dystonias, and the spasmodic contractions can cause posture deformity, head tremors, and pain. Over 1,000 cases of spasmodic torticollis have been treated, and the studies have reported improvement in 50 to 90% of the patients, depending on the dose and placement of the toxin. Comparatively large doses of botulinum toxin are used for injection at multiple sites. The larger quantities of toxin can diffuse to neighboring muscles, causing ptosis and other side effects.

Certain other diseases involving involuntary muscle movements have been successfully treated with botulinum toxin in a limited number of patients (reviewed in references 25, 98, 191, and 218). These include writer's and musician's cramps, hand tremors, spasmodic dysphonia and other laryngeal dystonias, neurogenic bladder as a result of spinal cord injury, spasms of the rectal sphincter (anismus), limb muscle spasms following stroke, leg spasms from multiple sclerosis, and spasticity in children with cerebral palsy. Botulinum toxin could potentially benefit humans who suffer from a variety of other hyperkinetic movement and muscle tone disorders including tics, tremors, bruxism, and pain brought on by muscle spasms (25, 98, 99, 218).

Although botulinum toxin is currently used for treatment of regional muscle groups, limited success has also been achieved with patients who suffer from hyperactivity of several muscle groups. Botulinum toxin has found limited use in tardive dyskinesic syndrome (221), a chorea marked by irregular dystonic movements and postures that can develop in mentally ill patients after treatment with neuroleptic medications. Some of these patients experience marked distress and suffer from disparate spasmodic disorders including repetitive blinking, backward arching of the head and trunk (retrocollis), rocking of the body, mouth grinding (bruxism), and involuntary voice sounds and grunting. In a pilot study, four patients were injected in diverse muscles and marked improvement was found in 2 weeks in all four individuals. Not all movement disorders in these patients improved, but several did including retrocollis, mouth control, and bruxism. Treatment of tardive dyskinesic syndrome by chemical denervation with botulinum toxin is complex because it involves different muscle groups. The strategy has been to focus toxin injection on the most involved muscle groups.

Generalized dystonias such as those observed in Parkinsonism present difficult problems for treatment because of the many muscles involved, but it is possible that if a proper method of administration could be worked out, these generalized conditions could be treated with toxin. One possible but untried route is the administration of low intravenous doses by which the toxin would spread regionally to many muscles.

Side effects of botulinum toxin. No adverse clinical effects of botulinum toxin have been found in patients who received low doses of botulinum toxin, e.g., ≤ 20 U. Single-fiber electromyography analysis has shown that injection of relatively large quantities of botulinum toxin (140 to 165 U) leads to toxin spread, weakening of distant muscles, and uncharacterized subclinical effects (116).

The primary side effect associated with local injections of botulinum toxin is weakening and ptosis of nearby muscles. One of the most prevalent and disturbing side effects is dysphagia, or the inability to swallow, and several patients have experienced upper airway obstruction after treatment with relatively high doses (>150 U) of botulinum toxin (25, 208). Dysphagia may be related to generalized weakness and inability to hold the head erect (75) or to weakening of muscles involved in swallowing. It may also be related to the dose and injection strategy used. To prevent dysphagia, Borodic et al. (23, 24) have recommended, on the basis of studies of toxin diffusion in tissues, the use of ≤ 100 U per treatment injected into several sites. Further research is needed to identify the lowest dose of toxin and sites of injections that will produce the desired control and prevent migration of toxin to neighboring muscle groups. Local side effects could be increased in patients who are being treated with drugs other than botulinum toxin that affect neuromuscular transmission (4).

There is interest among physicians in developing methods to prevent the spread of toxin to neighboring muscles. Scott (190) demonstrated that injection of antitoxin at the correct time following toxin injection partially prevented toxin migration. The currently available equine antitoxin could lead to undesirable reactions in some patients, and it would be valuable to have a source of human antibodies. In January 1991, human immunoglobulin G pooled from immunized human volunteers became available in a phase II clinical trial by the Orphan Drug Program of the FDA as a potential treatment for infant botulism (70). A similar pool of human

antibodies could also be useful to alleviate side effects of botulinum toxin injections without leading to patient reaction to the antiserum.

Changes in muscle tissue following botulinum toxin type A injections. Changes in skeletal muscles after botulinum toxin type A injection have been studied in animal models (53, 56, 57, 155). Duchen (56, 57) found that muscle fibers became atrophied and sprouting of nerve fibers was induced after injection of toxin into the leg muscle of mice. Sprouting of motor nerves was observed after 6 to 7 days and progressed for several weeks in the red soleus muscle; it occurred later in the predominantly white gastrocnemius muscle. Nerve sprouting occurred as complex branched arrangements which were apparently unable to establish functional connections for several weeks. The muscle fibers atrophied for 6 weeks or more and then increased in diameter to within normal limits within a few weeks. Changes in the localization and intensity of cholinesterase staining reflected the morphological changes. This work was important because it provided a new approach to quantitative characterization of reinnervation of denervated muscle. Pestronk and Drachman (155) evaluated motor nerve sprouting quantitatively after presynaptic blockade with botulinum toxin by measuring acetylcholine receptors with ^{125} I-labeled α -bungarotoxin. Muscle disuse was maintained by repeated injections of tetrodotoxin. They showed that the amount of sprouting was correlated with the number of acetylcholine receptors and was greatest in the botulinum-poisoned muscles. Sprouting was inhibited by α -bungarotoxin, suggesting that the acetylcholine receptors had an important role in inducing sprouting and muscle reinnervation. These results suggest that the use of a combination of botulinum toxin and α -bungarotoxin could prolong muscle paralysis.

In an approach derived from that of Duchen (56, 57), Borodic et al. (23–26) have used the albino rabbit as an animal model to quantitatively determine toxin spread from the site of botulinum toxin injection. Acetylcholinesterase staining, muscle fiber size analysis, and ATPase staining were used to establish a denervation gradient. A gradient effect up to 30 mm from the site of injection of 2 to 3 U of botulinum toxin type A per kg was found with respect to morphological changes in muscle fiber size and histological staining. At distances greater than 30 mm, there was substantially decreased staining and much less muscle atrophy. Very similar results were found in a study with crude type B toxin (26). The denervation indicated by histochemical staining and fiber size analysis appeared transient and lasted for about 3 months for both type A and B toxins. By using muscle biopsies, innervation sites were also determined with humans (23–25). Borodic et al. (23) have also used electrical stimulation to determine motor points and optimal injection sites in botulinum toxin therapy.

Immunity to botulinum toxin. There is considerable concern about the possibility that patients will develop antibodies and become refractory to botulinum toxin treatment, particularly when relatively high levels of botulinum toxin are injected repeatedly over several years. The dose of toxin required to trigger antibody formation in humans is not known. The minute quantities of toxin ingested in food-borne botulism are not sufficient to evoke antibodies. Recurrent episodes of type B and type E botulism have been documented in the same individual, supporting the notion that repeated exposure to botulinum toxin may not impart long-term immunity (6, 186). Repeated sensitivity to tetanus toxin in humans has also been reported (34).

Toxoid is commonly injected into laboratory workers to

stimulate antibodies and protect against accidents. The minimum dose of toxoid to elicit immunity in humans varies greatly with the individual and the toxoid preparation (3, 80, 197), but is probably similar to the immunological response to tetanus toxoid (73). Repeated injections of botulinum pentavalent toxoid after 0, 2, and 12 weeks and yearly boosters gave final titers of 3.2 IU of anti-A antibodies, 0.4 IU of anti-B antibodies, and 2.5 IU of anti-E antibodies per ml in a man (80). Antibodies were slow to develop, and a steep rise in the level of anti-A antibodies occurred in the fourth year of immunization. In an investigation of 77 patients subjected to the current U.S. schedule of toxoid injection at 0, 2, and 12 weeks, Siegel (197) reported that neutralizing antibodies to type A and B toxins were low or absent after the 12-week shot and significant titers were present only after yearly boosters. After the first booster, 74 (96%) had an anti-A antibody titer of 0.25 IU/ml or more, and only 44 (57%) of the subjects had an anti-B antibody titer of 0.25 IU/ml or more. (1 IU is defined as the amount of antibody neutralizing 10,000 MLD₅₀s.)

Antibody formation has been observed in a small number of patients injected with botulinum toxin (98, 191). To date, about 12 of more than 7,000 patients treated have developed antibodies to type A botulinum toxin. Six patients injected with 300 to 400 ng and one injected with repeated 100-ng doses within 30 days developed antibodies within 30 days (191). Antibodies have been demonstrated to reduce the beneficial effect of treatment (98). More work is needed to evaluate the incidence of antibody formation and other immunities in patients repeatedly treated with toxin over several years.

Properties and Uses of Serotypes of Botulinum Toxin Other than Type A

Seven known serotypes of botulinum toxin (A through G) have been isolated and characterized (213), and it is likely that types other than type A will be used clinically, particularly in patients who develop immunity to type A. Furthermore, evidence is accumulating to show that different types bind to different acceptors and may have subtle differences in their mode of action and that they could therefore complement type A in clinical applications. In the following sections, we review various basic science aspects of the botulinum toxins, especially as they pertain to potential clinical applications.

Botulism in humans. When botulinum toxin enters the circulation from contaminated food or infection, it can cause a severe paralytic disease. Types A, B, and E have most commonly been involved in human botulism (168, 213, 215), and type F has been the causative type in at least two outbreaks of food poisoning (78). Symptoms and severity of botulism differ depending on the serotype and amount of toxin ingested, suggesting possible differences in the mechanisms of intoxication (215). Clinical observations have indicated that type A food-borne botulism is often more severe and associated with higher mortality than botulism from other types (37, 52, 95). A rapid onset of neurologic signs indicates a more severe episode of the disease (38). Benign forms of botulism in which the course of the illness is milder and longer lasting have also been reported, particularly for type B (43, 100, 109, 209).

Botulism in humans generally manifests as a rapidly progressive symmetrical neuromuscular paralysis. Patients with botulism generally stay mentally alert during the poisoning unless anoxia sets in (108). Sudden respiratory or

cardiac arrests and airway obstruction, leading to death, can occur (109). Cardiac effects of botulinum toxin in animals and in humans have been reported (114, 215).

Botulinum toxin most often initially affects eye muscles supplied by susceptible cranial nerves, and the first signs of botulism are often blurred and double vision (215). As the paralysis progresses and peripheral nerves are affected, signs such as dry mouth, difficulty in swallowing, weakness in head and neck movements, and difficulty in breathing become apparent. In type A and B botulism, loss of musculature control manifests as ptosis and drooping of eye muscles, hypoactive gag reflex, and weakness in upper and lower extremities (95). Atypical symptoms including asymmetric or late-onset of neurologic signs, paresthesia, nystagmus, ataxia, and sensory abnormalities are not uncommon (31, 95, 215). Ingested botulinum toxin can paralyze all muscles of the body. Symptoms of botulism sometimes last for months, and recovery requires reinnervation by new nerve terminal axons and end plates. Weakness and fatigability may persist for 1 to 2 years (215). Recovery in adults is generally complete (38), but there are reports of central nervous system involvement in infant botulism (100a).

Since botulism is rarely encountered, it can be difficult to diagnose rapidly. Electromyography is useful for detection of decreased amplitude of muscle action potential in weakened muscle (215), and since conduction along the nerve axons is not altered by botulinum toxin, the proximal motor nerve conduction rates and distal latencies are normal (42). Botulism is confirmed by the demonstration of botulinum toxin in the patient's serum or stool or in suspect food by mouse assay and neutralization with type-specific antitoxin (52). Botulinum toxin has been found more often in the serum of patients with type E or B botulism than with type A, possibly because of the greater affinity of type A toxin for tissue acceptors.

The actual dose of botulinum toxin to cause food-borne intoxication in humans is debatable and depends on the individual, the source and type of toxin, and the amount ingested. Accidental cases of human botulism from toxin-contaminated food showed symptoms of botulism and occasionally death from as little as 0.1 to 1 µg (100 to 1,000 ng or 3,000 to 30,000 MLD₅₀s) (134, 140, 183), but results were quite variable, probably because of individual variation in the amount absorbed and the stability of the toxin in the gut. More data on toxicity is available for lower animals and monkeys. The lethal dose of crystalline toxin type A in mice was 1.2 to 2.5 ng (0.03 to 0.07 U)/kg (76, 80) and was 0.5 to 0.6 ng/kg for guinea pigs and rabbits (76). Scott and Suzuki (193) determined that the intramuscular LD₅₀ for juvenile monkeys (*Macaca fascicularis*) was ca. 39 U/kg (ca. 1.25 ng/kg) of body weight. Herrero et al. (91) reported a similar lethal dose of 40 U/kg by intravenous injection in *Macaca rhesus*. In Gili's table of lethal amounts of bacterial toxins, he reported botulinum toxin to be the most potent toxin known for primates, the lethal quantity of type A toxin being 0.5 to 0.7 ng/kg of body weight for monkeys and ca. 1 ng (30 U)/kg for humans (76). Larger quantities of types C₁, D, and E may be required to cause death in monkeys, whereas less type B is required (76). No data on intravenous toxicity are available for humans for botulinum toxins, but humans are probably as sensitive as guinea pigs and would be expected to be about as sensitive as monkeys.

Toxin production by the various serotypes of *C. botulinum*. Use of the various types of botulinum toxin in medicine will require a plentiful source of the toxins. The production of type A toxin under controlled conditions by the Hall strain,

as used for the preparation of toxin for human treatment, gives a uniform crystalline toxin in high yields. The toxin complexes of the other types have also been obtained by culturing and purification and could be useful clinically. However, the strain, medium composition, and culture conditions affect the yields and structures of the botulinum toxins.

To obtain the greatest quantity and highest quality of toxin, it is essential to maintain strains of *C. botulinum* that consistently produce high levels of toxin. However, the bacterium has a frustrating tendency under laboratory conditions to gradually lose its ability to produce high levels of toxin. Lewis and Hill (118) reported that the Hall strain made decreasing quantities of toxin on successive subcultures. Huhtanen (96) also reported that strains of type A and B toxins frequently become nontoxigenic during culture. A more complete understanding of the physiological and genetic factors that control toxin production will be valuable for the development of other types.

The highest levels of toxin in group I *C. botulinum* (proteolytic strains of types A, B, and F) are generally produced in cell populations that undergo rapid autolysis and do not sporulate (21, 27), although Siegel and Metzger (198) obtained titers of 6.3×10^5 U with the Hall strain in a fermentor without appreciable cell lysis. Toxin formation is poor during sporulation, and spores contain only small quantities of toxin (ca. 1% of that found in cytoplasm) (58, 77). Takumi et al. (216) reported the isolation of nontoxigenic variants of *C. botulinum* type A that had enhanced sporulation. The strain used for production of type A, the Hall strain, sporulates very poorly. Therefore, encouraging vegetative growth and autolysis and discouraging spore formation may be important for obtaining good yields of toxin.

Toxin formation is controlled by nutrition in group I and II *C. botulinum* (119, 152). Arginine delayed autolysis, affected sporulation, and repressed toxin formation in group I *C. botulinum* (28, 154). Toxin formation was repressed about 10,000-fold in group I, including the Hall A and Okra B strains, when abundant arginine was available in the medium (152), probably owing to nitrogen repression of toxin gene expression. Protease was also decreased by arginine in group I *C. botulinum*. In group II *C. botulinum* (nonproteolytic strains of serotypes B, E, and F), tryptophan availability repressed toxin formation, probably also in response to nitrogen sufficiency (119). These results indicate that fermentation conditions and mutant strains could be developed for improved toxin production.

Significance of complexes on toxin quality. The strain and culturing conditions also affect the quality of toxin that is produced. Schantz and Spero (181) found that botulinum toxins of the different serotypes occur in spent cultures as large protein complexes. In the ultracentrifuge the sedimentation coefficients for the complexes were 19S for type A, 16S for type B, and 13S for types C, D, E, and F. Sugii and Sakaguchi (211) showed that high-molecular-weight toxin complexes occur naturally in foods. It is now known that each of the types of botulinum toxin produced in food or in culture are conjugated proteins ranging in molecular weight from 300,000 to 900,000, comprising a molecule made up of one or two neurotoxic units of about 150,000 M_r , noncovalently conjugated to nontoxic proteins (168, 181, 213).

The formation of toxin complexes is very important for use of the toxins in medicine because the nontoxic proteins play an important role in maintaining the stability of the neurotoxic units. Isolated neurotoxic units were poorly toxic

to mice when administered orally (169, 170, 210). Peroral toxicity increased with incremental association of the neurotoxins with the protective proteins (150, 168–170, 210). The larger (19S and 16S) complexes of botulinum toxin types A and B were more toxic by the oral route and more resistant to acid and pepsin than were the smaller complexes. The isolated neurotoxins were rapidly inactivated by these conditions. Variations in the toxigenicities of different strains also probably depend on differences in the structures of the complexes. Ohishi (150) found that the oral toxicities differed considerably for the toxins of certain type A and B strains of *C. botulinum*. Of five B strains, Okra B produced the most potent toxin by oral challenge in mice. The 16S complex of the toxin was 700 times more potent than the 16S molecule from strain NH-2. A hybrid composed of the neurotoxin from NH-2 and the nontoxic components from Okra increased the oral toxicity close to that of the native Okra toxin, probably by protection of the neurotoxin in the gastric and intestinal tracts.

The size of the complex formed in types A, B, E, and F depends on the medium for bacterial growth. It has been known for years that some foods such as vegetables have high botulinogenic properties (134, 212). Sugii and Sakaguchi (212) showed that type A and B *C. botulinum* produced the stable 19S and 16S high-molecular-weight complexes in vegetables, whereas they produced the less stable 12S complex in tuna and pork. Nonconjugated neurotoxin was not found in any of the food substrates. They found that addition of iron or manganese to the growth medium resulted in a higher concentration of small toxin complexes (12S and 16S) in type A *C. botulinum*, suggesting an influence of metals on the size and stability of the complexes.

Biochemical and genetic properties of the neurotoxin component. The biochemistry of purified botulinum neurotoxins, particularly type A toxin, has been studied in considerable detail, and authoritative reviews are available (45, 81, 213). Neurotoxins have been purified for all serotypes except for type G; the type G toxin has been purified to a protein complex of high toxicity, but further purification resulted in substantial loss of toxicity (126, 146). Within a given type of toxin and strain of producing bacterium, there may be considerable heterogeneity in molecular structure and antigenicity, giving a mosaic structure (139). The neurotoxins all have high specific toxicities, from 10^7 to 10^8 MLD₅₀/mg of protein (213).

All types of neurotoxins are synthesized as single-chain protein molecules of about 150,000 M_r with low toxicity. The protoxins are released from the bacterium during culture (48). Those of proteolytic (group I) *C. botulinum* strains are cleaved by extracellular proteases into two-chain molecules consisting of an H (heavy) subunit of about 100,000 M_r and a L (light) subunit of about 50,000 M_r (45, 47, 48, 171, 196). Toxin preparations from nonproteolytic cultures require exogenous protease treatment for protoxin activation. The H and L chains are covalently linked by at least one disulfide and noncovalent bonds (45) and possibly a metal component (10, 11). The H and L chains of the neurotoxins can be separated by chromatography after treatment with dithiothreitol and urea (171). The isolated chains are not toxic by themselves but can be recombined under carefully controlled conditions to obtain active toxin (110, 123, 214, 230). Recently a chimeric toxin which retained considerable activity was prepared between the L chain of tetanus toxin and the H chain of botulinum toxin type A (230). Chimeric toxins composed of defined fragments, e.g., the H chain from botulinum toxin and the L chain from ricin, could be

valuable in medicine, but much work needs to be done on their formation and clinical testing.

During proteolytic cleavage the neurotoxins undergo a molecular change in shape that increases toxicity (48). The nicking region was recently reported to contain multiple target sites susceptible to more than one protease (45, 47). DasGupta and Dekleva have proposed that two peptide bonds in a short region are cleaved at different rates during maturation of type A toxin and that 10 amino acids are excised (45, 47). The control of proteolysis to increase stability could be useful in the preparation of the toxins for medicine, as has been achieved with tetanus toxin, and to obtain defined fragments for construction of toxins with desired properties.

The presence of metals in neurotoxins may affect their stability. Bhattacharyya and Sugiyama (10, 11) reported that chelators for iron and manganese inactivated purified type A botulinum toxin and tetanus toxin. Analysis of purified botulinum neurotoxin for metal content by neutron activation indicated that one atom of iron was present for each toxin molecule. It was suggested that metals may be involved in linkage of the H and L chains of botulinum and tetanus neurotoxins (10, 11). Kindler and Mager (107) found that metal availability in the culture medium affected the formation of toxin. Culturing *C. botulinum* in a medium containing EDTA did not inhibit growth but completely suppressed toxin formation. The biological activity of botulinum toxin may depend on a transition metal component, possibly Fe. The presence of metals could be important in maintenance of activity and protection from oxidation during drying and for long-term stability.

Recent genetic advances have increased our understanding of the structure and expression of the botulinum toxins. The genes coding for botulinum neurotoxin types A, B, and E are present in one copy on the chromosome in representative strains (14, 219). Genomic libraries of *C. botulinum* type A chromosomal DNA (strain 62A or NCTC 2916) were prepared on plasmids and transformed into *Escherichia coli*. For safety reasons, separate subfragments that were 2 kb or less in size and did not encode the entire neurotoxin gene were cloned. Open reading frames which encoded a sequence corresponding to a polypeptide of 1,296 amino acid residues, 149,425 M_r (14) or 149,502 M_r (219), were identified. The nucleotide sequences were in agreement with the partial nucleotide sequence reported by Betley et al. (9). The promoter of the BoNT/A gene was not transcribed in *E. coli*; this may have been caused by the frequent presence of codons in the promoter region that are not normally present in *E. coli*. Codon usage in the botulinum toxin gene was similar to that previously found for the tetanus toxin gene (61, 65, 66). Overall, 90.3% of the degenerate codons ended in A or U. An exception to the codon bias occurred for Lys codons, in which the frequency of AAA and AAG was nearly the same (24 AAA and 20 AAG) (219) compared with 98 AAA and 9 AAG for the tetanus toxin gene. In *C. botulinum*, AUG and UAA were translational initiation and termination codons, respectively, and strong bias was found for Arg and Ser codons. Binz et al. (14) found that the A+T content in the 5'-noncoding region of the type A and type E toxin genes was 80.4 and 80.3%, respectively, higher than in the coding regions, where 73.6 and 72.1% A+T were found. Examination of the upstream region indicated that transcription started 118 to 127 nucleotides upstream from the translation initiation site (14). Regions of dyad symmetry were demonstrated in the 3' noncoding region that may be involved in regulation of transcription. Binz et al. (14) con-

cluded that botulinum neurotoxin type A was translated from a monocistronic RNA and that the mRNA did not also encode the hemagglutinin and other nontoxic proteins of the natural toxin complex. Thompson et al. (219) also concluded that a single open reading frame was translated, giving only the neurotoxin protein.

The sequence of the type A neurotoxin gene indicated that botulinum neurotoxin A does not possess a signal peptide in the terminal coding regions, supporting the notion that it is not a secreted protein. Cys residues are conserved at positions 1060 and 1280 of botulinum (and tetanus) toxins, and Cys-454 occurs at the same position in *C. botulinum* type A, B, and E toxins and in tetanus toxin (61). Cys-454 is the sole Cys residue in the N-terminal region of the H chain and is probably involved in disulfide bridging of the L and H chains. Cys-430 is also located at an identical position in botulinum and tetanus toxin L chains. Sequence analysis of botulinum type A toxin indicated that the H chain of type A neurotoxin had six histidine residues arranged in a motif which the authors suggested could be involved in the biological action of the toxin, possibly penetration through the nerve membrane. The deduced amino acid sequences of botulinum toxins had about 33% homology to tetanus toxin, and the H chains showed higher homologies than the L chains (14, 219). No homologies were detected to other proteins including ADP-ribosylating clostridial toxins.

The DNA sequences have also recently been obtained for other botulinum toxins including type D, C₁, and E neurotoxins and the C₂ ADP-ribosyltransferase (13, 71, 72, 87, 105, 106, 157). Highly homologous regions were detected among the various neurotoxin gene sequences and tetanus toxin gene. The C₂ gene was found to be unrelated to C₁ and D neurotoxin genes.

Structure and properties of nontoxic proteins of the toxin complex. Relatively little is known concerning the biochemistry and genetics of the nontoxic proteins associated with neurotoxin in toxin complexes. The type A complex contains at least two nontoxic proteins, one of which has hemagglutinating properties (115). Strains of *C. botulinum* that do not produce hemagglutinin have been isolated, and these form smaller complexes (12S and 16S) than are normally found (19S) (111, 135, 211). The in vitro addition of hemagglutinin to the 12S complex results in formation of a 19S complex with increased stability (111). Binding of the hemagglutinin was inhibited by a heat-stable, dialyzable substance that has not been isolated (211).

DasGupta (44) reported that the hemagglutinins of type A and B toxins were constructed through aggregation of two small units of about 15,000 and 20,000 M_r . Recently, Somers and DasGupta (204) studied nontoxic proteins from type A, B, C₁, and E toxin complexes. The proteins isolated from types A, B, and E had various degrees of hemagglutinating activity (Hn⁺), while the protein from type E had no hemagglutinating activity (Hn⁻). The type A Hn⁺ and type B Hn⁺ were serologically cross-reactive. Type A Hn⁺, type B Hn⁺, and type C Hn⁺ were isolated as large aggregates (220,000 to 900,000 M_r), which were separated into multiple subunits of $\approx 17,000 M_r$ by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The type E Hn⁻ of 116,000 M_r did not aggregate. The sequences of the 10 to 33 amino-terminal regions of the 17,000, 21,500, 35,000, and 57,000 M_r subunits of type A Hn⁺ and type B Hn⁺ were determined. Each of the subunits had a unique sequence, indicating that the subunits were not homomers of smaller units. The subunits types A and B had remarkably similar

sequence identity; i.e., the 21,500 M_r subunits were identical and the 57,000 M_r subunits had 80% identity.

An understanding of the genetics of the hemagglutinin component of the toxin complexes is also developing. Oguma et al. (148) showed several years ago that the capacity to produce hemagglutinin in *C. botulinum* type C was transferred by phages either separately or together with toxin. Physical linkage of a hemagglutinin gene and toxin gene was confirmed, and it was shown that the toxin and hemagglutinin genes were transcribed in opposite directions. Tsuzuki et al. (224) cloned the gene encoding the main component of hemagglutinin produced by *C. botulinum* type C. The complete nucleotide sequence of the gene indicated that it encoded a protein of 33,000 M_r . At 62 bp downstream from the termination codon of the cloned 33,000 M_r subunit of type C Hn⁺ was an initiation codon followed by a coding sequence for at least 34 amino acids. Somers and DasGupta (204) found that the derived amino acid sequence of this open reading frame had 73 to 84% sequence identity with the 17,000 M_r subunits of type A Hn⁺ and type B Hn⁺ and significant similarity with the N terminus of type E Hn⁻. This observation raises the interesting possibility that genes for some of the subunits have a similar genetic arrangement and a common ancestral origin. It is interesting that a sequence homology has been proposed between tetanus toxin and the hemagglutinin of influenza virus (138), indicating a possible viral origin of the neurotoxin.

New findings in the mechanisms of action of the different types of botulinum toxins. Botulinum neurotoxins A to G are antigenically distinct yet have a number of structural and mechanistic similarities. All of the neurotoxin types cause a chemical denervation at the myoneural junction by inhibiting acetylcholine release. However, there appear to be subtle differences in the mechanisms of action of the neurotoxins. Toxin types A and E, type B, and type F apparently bind to distinct high-affinity receptor regions with similar affinities (K_D 10^{-9} to 10^{-10} nM) in synaptosomes and at murine neuromuscular junctions (20, 45, 62, 110, 128, 228, 233). Binding may occur in regions composed of sialosyl residues and protein (184) and may first involve low-affinity association of the H chain followed by high-affinity attachment. In addition to binding to different receptor regions on the nerve surface, botulinum toxin types A and B have been reported to affect neurotransmitter release differently (74, 137). Electrophysiological studies have shown that type A affects asynchronous neurotransmitter release, whereas type B does not (137). Furthermore, an increase in the intracellular Ca^{2+} concentration by ionophore treatment reverses inhibition by type A but not type B in synaptosome preparations (5), and aminopyridine more readily reverses type A than type B inhibition at the myoneural junction (74).

Both the H and L chains of the neurotoxin may be required for poisoning in invertebrate systems (123, 158). In mammalian peripheral motor nerve terminals, the L chain alone is active after it is internalized (15, 49). The precise mechanism of blockade by the L chain is unknown, but it must affect a general and important component of the secretory machinery in various classes of neurons. Botulinum toxin blocks the release of several classes of neurotransmitters at central and peripheral neurons (15, 120). Recently, it has been proposed that the L chain may act at an intracellular membranous or cytoskeletal site to inhibit neurotransmitter release (5, 120). Because of the extraordinary toxicity of botulinum toxin, it is likely that it has enzymatic activity and acts catalytically or triggers a cascade of events that decrease neurotransmitter release. The intracellular

substrate of botulinum toxin remains an elusive grail that is being pursued by several laboratories.

An objective in treatment of hyperactive muscles is to prevent possible systemic reactions which could result from spread of toxin through the blood. Antibodies could be used therapeutically by application to the injection site to help limit the diffusion of toxin and alleviate side effects such as ptosis (190), or it may also be possible to add the nontoxic H chain after toxin injection to block toxin binding to neighboring nerves. The most desirable approach to avoid spread would be to confine the paralyzing action within the presynaptic nerve. An interesting recent development is the finding that stabilized mRNA (3' polyadenylated and 5' capped) corresponding to the nucleotide sequence of tetanus toxin gene (L chain) injected into *Aplysia californica* cholinergic neurons in a bath depressed neurotransmitter release in less than 1 h (136). Similar results were found for mRNA of the L chain of botulinum A toxin, but only when the H chain was also added to the bath. The L chains of tetanus and botulinum neurotoxins were demonstrated to be synthesized in the presynaptic neurons, and onset of toxin action was slower than that of neurotoxins injected directly.

The subtle differences in botulinum toxin mechanisms among the various serotypes suggest that combinations of botulinum toxins could be more effective in clinical practice than any one type alone. Further work is needed to produce, stabilize, and test the clinical effectiveness of different types. Preliminary work indicates that types B (26) and F (187) are useful in controlling certain spasmodic muscle disorders.

Clinical use of pure neurotoxin compared with toxin complexes. Most recent information concerning the structure and pharmacology of botulinum toxin has been obtained with purified neurotoxins, but it is unlikely that these will be used in a clinical setting. The toxin complexes are much more stable than neurotoxins and can be diluted and formulated with retention of toxicity. Pure neurotoxins can be kept for several weeks to months in solution in the cold but are inactivated on dilution, formulation, and drying. No clinical trials on primates have been performed with purified neurotoxins.

Sellin et al. (195) reported that injection of 1 to 20 U of crystalline type A botulinum toxin into the lower hindlimb of the rat produced a paralysis that lasted for several days. In contrast, injection of more than 1,200 U of type B neurotoxin was required to produce paralysis. The duration of paralysis was compared after injection of 20 U of type A or 5,000 U of type B toxin. Type A toxin caused paralysis for up to 7 days after injection, whereas type B toxin caused paralysis for only 3 days and twitching became evident at 5 to 7 days. It was also reported (104, 194) that pure type A neurotoxin was much more effective than type E or F neurotoxin in eliciting lasting paralysis in the lower hindlimb of rats.

Tetanus Toxin

Tetanus toxin, like botulinum toxin, is produced by an anaerobic sporeforming rod that has a similar morphology to *C. botulinum* (86). Unlike botulinum toxin, tetanus toxin can enter into the central nervous system by retrograde intraxonal transport through motor nerves (17, 81, 132). It causes uncontrolled spasms of voluntary muscles by blocking the release of inhibitory transmitters including γ -aminobutyric acid and glycine (132). Tetanus toxin also has significant activity in decreasing acetylcholine release in cholinergic peripheral nerves when injected locally (54) and could possibly be used as an adjunct to or independently

from botulinum toxin for control of hyperactive muscles if the acquired immunity could be overridden. Tetanus toxin could also be used pharmacologically to transport substances to the central nervous system (17, 18). The biochemistry and pharmacological activities have been recently reviewed (17, 81). Here we consider aspects of the toxin that pertain to tetanus toxin production, stability, and potential use in medicine.

Crystalline structure. Tetanus toxin was originally purified by Pillemer et al. in the 1940s by precipitation methods. They obtained toxin crystals by carefully carrying out repeated precipitations in methanol and controlling the ionic concentration, pH, and toxin concentration (156). Tetanus toxin, like botulinum toxin, is a simple protein that does not contain lipid or carbohydrate (156, 165, 166). Unlike botulinum toxin, tetanus toxin does not occur complexed with protecting proteins and will not survive gastric passage or cause food poisoning in humans.

Although crystals of tetanus toxin were obtained in the 1940s by Pillemer et al. (156) from cold alcohol solutions, crystallization was not confirmed by others for several years. More recently, two-dimensional crystals of tetanus toxin have been isolated from ammonium sulfate solutions after incubation for several weeks at 4°C (40, 167). Robinson et al. (167) obtained two-dimensional arrays of native tetanus toxin formed at the interface between a solution of the toxin and a phospholipid monolayer containing ganglioside. Crystalline arrays were obtained only when all three components (toxin, phospholipid, and ganglioside) were present. The three-dimensional structure of tetanus toxin at 14-Å (1.4-nm) resolution appeared as an asymmetrical three-lobed structure that could interact with the phospholipid monolayer in two possible orientations (167). The analysis indicated that tetanus toxin is composed of differently shaped domains with different functions.

Biosynthesis and activation of tetanus toxin. Tetanus toxin is synthesized intracellularly as a single polypeptide of 150,000 M_r that is released from the cells on autolysis and is then modified by proteases present in the medium (81, 88, 89). The single-chain molecule is difficult to isolate (81), and proteolytic modifications of the toxin have caused considerable difficulties in the accurate characterization of the molecule. Single-chain toxin can be prepared from washed extracted bacterial cells (88, 162) and by inclusion of protease inhibitors and use of specific purification procedures (7, 165, 231). Purified preparations containing protease inhibitor can be stored for 4 to 6 weeks without proteolytic modifications and loss of toxicity (165).

Conversion of tetanus toxin to the nicked form increases toxicity (7, 81). *C. tetani* forms proteases that produce nicking in culture (231), but many other endoproteases will also activate the toxin (2). Three regions in the molecule are particularly susceptible to nicking (81, 129). Mild trypsin treatment of intracellular single-chain toxin yields two chains of about 95,000 and 50,000 M_r . The modified tetanus molecule is strongly held together by noncovalent bonds, and reduction of disulfide does not result in separation of the chains. Strong denaturants such as urea or SDS (81, 166) or purification techniques such as isoelectric focusing (2, 231) are required to dissociate the chains.

The H chain of tetanus toxin possesses a particularly susceptible region that can be cleaved with proteases such as trypsin or papain, yielding two fragments (B and C) (2, 89). The isolated H and L chains and fragments B and C are poorly toxic compared with intact tetanus toxin (2). Ahnert-Hilger et al. (2) reported that the nicking sites contributing to

toxicity are located within a region spanning no more than 17 amino acids, and the N and C termini are not altered during the modification. The separated chains were reconstituted to active toxin. By reconstitution experiments, the L chain was demonstrated to possess the paralyzing activity in isolated nerve-muscle preparations. The H chain is required for toxin entry into the nerve tissues and for axonal transport (2).

Large-scale production of tetanus toxin. Tetanus toxin is produced in deep culture by methods similar to those described for botulinum toxin. J. Howard Mueller, Pauline Miller, and associates at Harvard Medical School developed the methods currently used for production of tetanus toxoid. They experienced much frustration in obtaining consistent quality and the high titers of toxin required for toxoid demand (121, 142-144). They realized the importance of medium formulation in obtaining good-quality tetanus toxin, "If it were only possible to grow the tetanus organism on a medium containing only chemically defined substances of low molecular weight, it should become a relatively straightforward matter to study and control the factors involved in toxin production, and to obtain a uniform product free from any possible antigenic material other than the specific substance desired." (141). An extensive study was carried out to identify factors controlling tetanus toxin formation (143). On fractionation of components of the medium, the basis of good production was determined to be present in a pancreatic digest of casein. The key to good toxin production by *C. tetani* was later determined to be limitation of histidine (144). Abundant free histidine drastically decreased toxin production, while its limitation strongly increased titers (144). Since histidine is required for growth of *C. tetani*, it was necessary to find a method to limit the nutrient without stopping growth. Mueller and Miller found that providing histidine-containing peptides (e.g., glycyl-histidine) or histidine esters (e.g., acetyl-histidine) stimulated toxin production. Latham et al. (117) developed a protein-free medium which is currently used for tetanus toxin production. Mueller and Miller also isolated a high-producing strain (the Harvard or Massachusetts strain) (142) that is still widely used by many laboratories.

Tetanus toxin synthesis was found to be repressed by the addition of excess amino acids to the medium (223). Melanby (131) reported that glutamate addition to the Mueller and Miller growth medium decreased toxin formation but shortened the time necessary for autolysis. The results indicate that nitrogen nutrition controls toxin regulation in *C. tetani*. It is interesting that excess nitrogen also represses botulinum toxin synthesis in *C. botulinum* (119, 152). Careful adjustment of the levels of iron salts in the medium is also necessary for good tetanus toxin production (67, 142). The mechanisms of nutritional regulation and its importance in the biology of *C. tetani* and *C. botulinum* have not been further studied to our knowledge.

Tetanus toxin, like botulinum toxin, is produced in highest quantities by nonsporulating cultures (85, 145). Highly toxic cultures autolyzed thoroughly and did not form endospores during culture. During culture, tetanus toxin was present within the cell and was not released until cultures lysed (141, 162). As with *C. botulinum*, it appears that toxin formation is associated with autolytic growth and inversely associated with sporulation (145, 153). It would be of interest to determine whether specific transcription factors, e.g., sigma factors, regulate transcription of the toxin gene and whether these are preferentially expressed or activated in autolytic growth compared with sporulation.

Genetics of tetanus toxin. Tetanus toxin production has

been recognized as an unstable property for many years (68, 142). Attempts were made early to correlate the toxigenicity with the presence of bacteriophage. Phages were induced in *C. tetani* by treatment with mitomycin C, but induction did not affect toxin production (159, 160). Nontoxic mutants were readily isolated at high frequency (0.8 to 3.2%) from the Harvard strain A47 by treatment with various mutagenic agents including *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine, UV light, and rifampin (85). Hara et al. (85) found that cured, nontoxic strains still carried phages and proposed that plasmids could be involved in toxigenesis. Laird et al. (112) showed that toxigenicity was associated with the presence of a single large plasmid in 21 strains of diverse origin. Nontoxic derivatives were isolated, and each strain lost its plasmid. Two naturally occurring nontoxic strains were examined, and one was free of plasmids while the other contained a single large plasmid (112). The strains derived from the Harvard strain all contain a plasmid of 49 kb, which had identical restriction nuclease digestion patterns (112). By construction of a pool of nucleotide probes corresponding to the *N*-terminal amino acid sequence of tetanus toxin, Finn et al. (69) located the tetanus toxin gene to plasmid-related sequences. Surprisingly, strains with deletions in the plasmid still hybridized to the probes, suggesting that toxin gene sequences were still present but were not expressed to active product.

Eisel et al. (61) used a pool of oligonucleotides (heptadecamers) made up of all possible DNA sequences for *N*-terminal amino acids 8 to 13 of fragment C of tetanus toxin and screened plasmid preparations from toxigenic and nontoxic variants of the Harvard strain. Overlapping sequences that spanned the entire toxin gene were obtained from eight clones. The DNA fragments encoding tetanus toxin specified an open reading frame of 1,315 amino acids of 150,700 *M_r*. The open reading frame begins with an initiation codon for methionine, but purified toxin, like botulinum toxin, possesses proline at its *N* terminus and contains serine at the *N* terminus of the H chain (61). The molecular weights of the H and L chains calculated from the amino acid sequence are 98,300 and 52,288, respectively. Partial sequences reported for peptide fragments from the L chain (166) are only partly consistent with those obtained by nucleotide sequencing. The discrepancy may be caused by the extensive proteolytic processing that tetanus toxin undergoes following cell autolysis.

Computer searches using the primary sequence of tetanus toxin have not revealed primary structural similarities with any proteins other than botulinum toxin. Analysis of the primary sequence has also provided evidence that tetanus did not evolve by duplication of sequences within the H and L chains, which was earlier suggested by the similarities in amino acid compositions of the H and L chains (217) and by immunological similarities probed with monoclonal antibodies (227).

The availability of cloned tetanus gene fragments has enabled the production of tetanus toxin fragments for potential use as vaccines. Makoff et al. (124) expressed tetanus toxin fragment C in *E. coli* as 3 to 4% of the total cell protein. However, the coding sequence for fragment C is A+T rich and contains several codons rarely used in *E. coli*. Production was improved by replacing the coding sequence by a sequence optimized for codon usage in *E. coli* (125). More efficient translation of the mRNA was the most important factor for the increased expression. When the modified coding sequence was combined with improved promoter strength, fragment C was expressed as 11 to 14% of the cell

protein. Halpern et al. (83) cloned the sequence encoding fragment C and showed that the fragment expressed in *E. coli* retained ganglioside- and neuronal cell-binding activity. Recombinant fragment C was purified in one step by affinity chromatography. Recombinant fragment C was also immunogenic in mice and elicited antibodies that protected against tetanus toxin challenge. The availability of recombinant fragment C should be useful for a variety of research applications and for production of toxoid.

Pharmacological and medical applications of tetanus toxin. Tetanus acts primarily in the central nervous system and causes hyperactivity of the motor system and a spastic paralysis. Under specific conditions, tetanus toxin also inhibits peripheral neuromuscular transmission, resulting in a flaccid paralysis (82, 130). Tetanus toxin resembles botulinum neurotoxin in its structure and mode of action (81). Botulinum and tetanus neurotoxins have significant homology at the amino-terminal regions of the L and H chains, suggesting that at least portions of the respective genes evolved from a common ancestral gene.

Similarities in structure of tetanus and botulinum toxins have also been demonstrated in serological studies. Antibodies to type C botulinum toxin cross-reacted with other botulinum toxin serotypes and also reacted with tetanus toxin (149, 225). Tsuzuki et al. (225) found that a monoclonal antibody raised against botulinum toxin type E cross-reacted with botulinum toxin types B, C₁, and D and with tetanus toxin. Halpern et al. (84) developed antibodies against defined regions of the tetanus toxin to identify regions shared by tetanus and botulinum toxins. Synthetic peptides that corresponded to different regions of tetanus toxin were prepared and coupled to bovine serum albumin, which were used to immunize mice. Eleven of 13 peptides elicited antibodies that reacted with tetanus toxin in an enzyme-linked immunosorbent assay. Of 10 anti-tetanus peptide antibodies that reacted well with tetanus toxin, 1 reacted with botulinum toxin types B, C₁, and E but did not recognize type A. This antibody was made with a peptide corresponding to the amino-terminal end of the tetanus L chain, suggesting that this region is important in intoxication and that its structure is conserved in the two toxins. The antigenic region may be shielded in the native toxin but exposed on denaturation. Halpern et al. (84) also tested human tetanus immune globulin and mouse anti-tetanus serum for cross-reactivity with botulinum toxin, but none was detected. These results suggested that native forms of tetanus and botulinum toxins have little common surface antigenicity. This conclusion was also reached by Tsuzuki et al. (225), who prepared 306 monoclonal antibodies against the L chain of botulinum toxin type E and found that only 1 reacted with the other botulinum toxin types and with tetanus toxin.

Tetanus toxin has the unique ability to enter into the central nervous system through motor neurons. Because of the ability to travel up motor nerves, tetanus toxin or nontoxic fragments could provide a unique neurotropic agent to transport substances to the central nervous system (16-19). A 45-kDa nontoxic fragment, B-II₆ (fragment C), that bound to toxin-binding sites on neuronal cell membranes and transported retrogradely from the axonal endings within the muscle to the motoneuronal perikaria was isolated (19). Bizzini et al. (18) constructed hybrid molecules consisting of the neurotropic fragment C and the I_{bc} fragment derived from tetanus toxin connected through disulfide linkage. The I_{bc} fragment was specifically carried to the central nervous system. Bizzini (17) also reported that fragment C

could compete with rabies virus for attachment to binding sites on neuronal cells and affected the rate of spread of rabies virus. Cloning and expression of high levels of fragment C should lead to further studies of targeted delivery to the central nervous system and possibly to control of virus infections.

Tetanus toxin also can act peripherally, causing a flaccid paralysis in the manner that characterizes botulinum toxin (54). H chains of both botulinum and tetanus toxins form channels in lipid bilayers (94). The H₂ fragment of the H chain of tetanus toxin was found to antagonize the action of botulinum toxin in phrenic nerve-hemidiaphragm preparations (201, 202). Tetanus toxin is about 2,000 times more toxic at central inhibitory nerves than at peripheral synapses (12, 54) and is about 1,000 times less toxic than botulinum toxin type A at the myoneural junction (82). Dreyer and Schmitt (55) proposed that tetanus toxin and botulinum toxin type A act at different sites in nerve inhibition of transmitter release. Botulinum toxins type B (74, 195), D (54), and F (104), but not A (74), appeared to act in a similar manner to tetanus toxin in affecting transmitter release from the myoneural junction. The combination of botulinum and tetanus toxins or the construction of chimeras could potentially be used to control neurological disorders.

MICROBIAL NEUROTOXINS THAT ALTER VOLTAGE-GATED SODIUM CHANNELS

Other microbial neurotoxins impair muscle activity in a way different from botulinum and tetanus toxins by their effect on the action potential at the sodium channel of a nerve axon. Saxitoxin and tetrodotoxin are two classical examples of microbial neurotoxins that block or close the passage of sodium ions through the channel. Toxins produced by other dinoflagellates also produce changes in the action potential at the sodium channel and are briefly described below.

Saxitoxin is a potent rapidly acting neurotoxin produced by the marine dinoflagellate *Gonyaulax catenella* (206) and some bacteria (102, 122). Like botulinum toxin, it was first observed as a food-borne toxin, causing food poisoning that occurred only at certain times from consumption of mussels, clams, and some other shellfish that are plankton feeders. Consumption of toxic shellfish results in symptoms described as numbness of the lips and fingertips within a few minutes followed by a progressive paralysis of the arms and legs along with the development of labored breathing and asphyxia. Death may occur within 2 to 24 h, depending upon the dose, from respiratory paralysis. After survival for 24 h the prognosis is good, and no lasting effects of the toxin have been observed. The oral dose that causes death from accidental consumption of toxic shellfish by humans is 1 to 4 mg (5,000 to 20,000 mouse units) depending upon the age and physical condition of the patient. A mouse unit (MU) is defined as the minimum amount needed to cause the death of an 18- to 22-g white mouse in 15 min, which is usually the maximum time in which death will occur (174, 205).

Saxitoxin was first purified and crystallized by Schantz et al. (172, 179), and its structure was determined by X-ray crystallography by Jon Clardy (175). Purified saxitoxin is a very hygroscopic water-soluble toxin and is described chemically as a tetrahydropurine base with pK_ss at 8.5 and 11.5. It has a molecular weight of 299 as the free base. It has no UV absorption above 210 nm. As the dihydrochloride salt it is a white solid that is stable in acidic solution but loses activity above pH 7. The paralyzing action of saxitoxin or its

binding at the receptor of the sodium channel depends upon the presence of a hydrated ketone group in a particular position in the molecule. Reduction of this group to the alcohol results in the loss of over 99% of the binding and paralyzing activity.

The neurotoxic action of saxitoxin is due to its specific binding, even at extremely low concentrations (10^{-9} M), at the sodium channel of excitable membranes and preventing the passage of sodium ions through the sodium channel, thus blocking an impulse. The action or binding is concentration dependent, and binding is reversible. Controlled application of the toxin has been suggested as a possible local anesthetic. The effective dose in animals is relatively close to the lethal dose, as indicated by the steepness of the response curve, and pharmaceutical companies have not pursued its use in humans. However, when saxitoxin is mixed in small amounts with many classes of anesthetics, the effectiveness of the anesthetic action is greatly extended (1). The addition of 1 µg of saxitoxin to a 1% solution of a typical anesthetic (1 part in 10,000) such as procaine increased the time of effective action two- to threefold (1). The result is not an additive one (1). The addition of saxitoxin to procaine as well as to other anesthetic compounds will also reduce the dose required to obtain a desired effect. The reason for this unusual action of saxitoxin with anesthetic compounds has not been fully explained, but the molecule must play an important part in nervous function in the presence of other substances that act on the nervous system. Saxitoxin and tetrodotoxin have been important in the establishment and characterization of the sodium channel in myelinated and unmyelinated nerve membranes (90, 93, 102, 163, 164) and for the study of related diseases such as multiple sclerosis.

Another species of dinoflagellates, *Gonyaulax tamarensis* var. *excavata*, produces saxitoxin substituted with sulfate and sulfonic acid groups (63, 102). These substituted toxins have a lower specific toxicity or binding at the sodium channel than saxitoxin does, but they should not be overlooked for possible medical use.

Tetrodotoxin was originally found in the roe, ovaries, and liver of the puffer or globe fish (*Tetraodonidae*) caught in the western Pacific ocean and was at first believed to be exclusively produced by this fish. More recently it has also been found in various other animals including the California newt, octopus, and frog (234) and in marine bacteria (51, 199, 220, 235). Dinoflagellates have been proposed as the original source of the toxin in puffer fish, which acquire it through the food chain (234).

The action of tetrodotoxin is like that of saxitoxin in blocking the sodium channel of excitable membranes of nerve and muscle tissue. In fact, it has been shown that both tetrodotoxin and saxitoxin block the inward current of sodium ions at equally low concentrations of 10^{-7} to 10^{-9} M and occupy the same receptor sites at the sodium channel (63, 103). The basic structure of tetrodotoxin is markedly different from that of saxitoxin and is chemically described as aminoperhydroquanzoline, with a molecular weight of 319. Although the two toxins are basically different in structure, they may be similarly classified as heterocyclic guanidines because of the guanidium group common to each toxin. Kao and Nishiyama (103) first proposed that the guanidinium moieties of each toxin might enter at the sodium channel like guanidine and that the bulk of the remaining part of the molecule prevented the passage of the sodium ion.

Although this hypothesis may be consistent with many aspects of the action of the toxins, it appears that the chemical makeup of the molecule as well as the guanidine

group is involved. The reduction of the hydrated ketone group to an alcohol in the saxitoxin molecule completely destroys its effectiveness as a blocker of the sodium channel, and changes in the structure of tetrodotoxin also affect its bonding (102). The purpose here is to point out in a general way the nature of the two toxins and how they might affect the action of other toxins used for treatment of hyperactive muscles. The fact that saxitoxin enhances the action of local anesthetics has raised some thoughts on the relation of one toxin to another on an excitable membrane. Reviews by Catterall (36), Kao et al. (102, 103), and Borison et al. (22) give detailed descriptions of the action of the microbial neurotoxins saxitoxin and tetrodotoxin (binding site 1 at the sodium channel) and compare them with neurotoxins from other nonmicrobial sources that affect the sodium channel, such as veratridine, aconitine, batrachotoxin, grayanotoxin, and the low-molecular-weight basic polypeptide toxins isolated from scorpion venoms, fish-hunting cone snails, and sea anemone nematocysts (binding site 2 at the sodium channel). These reviews point out the various mechanisms by which toxins might affect the nervous system via action at the sodium channel. From the proposed action it seems reasonable to assume that there may be value in the use of combined toxins for control of nervous activity.

It is quite interesting that the action potential at the sodium channel is also affected by certain substances, such as guanidine and 3,4-diaminopurine, that reverse or bypass the blocking action of botulinum toxin. Although these substances are not particularly good antidotes for the toxin, their action indicates a relationship between the action potential at the sodium channel and the liberation of a neurotransmitter at the nerve ending. One might assume, therefore, that substances such as saxitoxin, tetrodotoxin, or others that alter the action potential at the sodium channel should warrant further investigation for possible medical application. Guanidine, an effective substitute for sodium in action potential generation in excitable membranes (93), is also reported to relieve symptoms of botulism (39), suggesting that there may be interactions of toxins at the myoneural junction, a field that warrants further study.

Besides the microbial neurotoxins described thus far, there are other, less well understood microbial neurotoxins that may be found valuable for nerve and muscle control mainly because of their action at the sodium channel. *Gymnodinium breve*, a marine dinoflagellate responsible for the Florida red tides and the tremendous fish kills in that area, produces several toxins, two of which are neurotoxins designated brevetoxins A and B, that have some action at the sodium channel (22). These two toxins are lipid-soluble polyethers with a molecular weight around 900. Brevetoxin A has an indirect action on the sodium channel in that it enhances channel activity in the presence of toxins that bind to receptor site 2 at the sodium channel, but not to receptor site 1.

Gambierdiscus toxicus, a tropical reef-dwelling dinoflagellate, produces several toxins, including one designated ciguatera toxin, which opens voltage-dependent sodium channels in cell membranes (186). This toxin is a lipid-soluble polyether with a molecular weight of 1112 and is concentrated as it is passed up the food chain to large predatory reef fish consumed by humans. The disease in humans affects both gastrointestinal and neurological systems. The neurological symptoms usually begin within 24 h and may last a month or more, indicating nerve blockage or damage requiring regeneration of nervous tissue. Afflicted persons experience cir-

cumoral paresthesias, paresthesias or paralysis of the extremities, and muscle pain.

Natural blooms of the freshwater blue-green alga (cyanobacterium) *Aphanizomenon flos-aquae* which occur periodically in lakes of the northern United States and certain provinces of Canada have caused poisoning of farm animals from drinking the water. This organism produces several toxins including saxitoxin and neosaxitoxin. Another species of this group, *Anabena flos-aquae*, produces a substance that affects acetylcholine receptors in muscle membranes (35, 97). Some mycotoxins affect the nervous system in various ways. Slaframine, upon biological conversion to a quaternary amine, causes excessive salivation in farm animals and acts similarly to acetylcholine (30, 41). These organisms and other microorganisms produce other neural toxins, but little is known of their action and importance in pharmacology and physiology.

CONCLUSIONS

Botulinum toxin type A has been found useful for the treatment of many hyperactive muscle disorders by intramuscular injection, and the FDA has licensed the toxin for treatment of strabismus, blepharospasm, and hemifacial spasm. It is the first microbial toxin to be used for human treatment. Because it is injected into humans, purity is of prime importance and, therefore, during the production by culturing and purification, it must not be exposed to any substances that might be carried in trace amounts to the crystalline toxin and cause undue reactions in the patient. Injection of the toxin into muscle tissue has opened a new field of investigation into the action of the toxin on muscle and nerve tissue and has been beneficial to many humans who suffer from dystonias.

Types of botulinum toxin other than type A toxin and perhaps tetanus toxin may be useful for human treatment if patients develop immunity to type A toxin. Saxitoxin stimulates and prolongs the action of local anesthetics, suggesting the use of combined toxins for human treatment. Some microbiological toxins are described for possible use alone or combined with botulinum toxin for medical treatment.

ACKNOWLEDGMENTS

We thank the Food Research Institute and its member companies and the U.S. Food and Drug Administration for supporting research on botulinum toxin and saxitoxin.

Valuable discussions with H. Sugiyama and B. R. DasGupta on botulinum toxin are gratefully acknowledged. We appreciate the collaboration over the years with Alan B. Scott in development of botulinum toxin for medicine.

REFERENCES

1. Adams, H. J. F., and B. H. Takman. January 1977. Pharmaceutical local anaesthetic composition employing saxitoxin. U.S. patent 4,001,413.
2. Ahnert-Hilger, G., M.-E. Dauzenroth, E. Habermann, A. Henschel, K. Kriegelstein, F. Mauler, and U. Weller. 1990. Chains and fragments of tetanus toxin, and their contribution to toxicity. *J. Physiol. (Paris)* 84:229-236.
3. Anderson, J. H., Jr., and C. E. Lewis, Jr. 1981. Clinical evaluation of botulinum toxoids, p. 233-246. In G. E. Lewis, Jr. (ed.), *Biomedical aspects of botulism*. Academic Press, Inc., New York.
4. Argov, Z., and F. L. Mastaglia. 1979. Disorders of neuromuscular transmission caused by drugs. *N. Engl. J. Med.* 301:409-413.
5. Ashton, A. C., and J. O. Dolly. 1991. Microtubule-dissociating

- drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B. *J. Neurochem.* 56:827-835.
6. Beller, M., and J. P. Middaugh. 1990. Repeated type E botulism in an Alaskan Eskimo. *N. Engl. J. Med.* 322:855.
7. Bergey, G. K., W. H. Habig, J. I. Bennett, and C. S. Lin. 1989. Proteolytic cleavage of tetanus toxin increases activity. *J. Neurochem.* 53:155-161.
8. Bernard, C. 1875. *La science experimentale*, p. 237. Bailliere, Paris.
9. Belley, M. J., E. Somers, and B. R. DasGupta. 1989. Characterization of botulinum type A neurotoxin gene: delineation of the N-terminal encoding region. *Biochem. Biophys. Res. Commun.* 162:1388-1395.
10. Bhattacharyya, S. D., and H. Sugiyama. 1989. Inactivation of botulinum and tetanus toxins by chelators. *Infect. Immun.* 57:3053-3057.
11. Bhattacharyya, S. D., H. Sugiyama, P. Rust, and D. Lacey. 1988. Evidence that subunits of type A botulinum toxin need not be linked by disulfide. *Toxicol.* 26:817-825.
12. Bigalke, H., F. Dreyer, and G. Bergey. 1985. Botulinum A neurotoxin inhibits noncholinergic synaptic transmission in mouse spinal cord neurons in culture. *Brain Res.* 360:318-324.
13. Binz, T., H. Kurazono, M. R. Popoff, M. W. Eklund, G. Sakaguchi, S. Kozaki, K. Kriegstein, A. Henschen, D. M. Gill, and H. Niemann. 1990. Nucleotide sequence of the gene encoding *Clostridium botulinum* neurotoxin type D. *Nucleic Acids Res.* 18:5556.
14. Binz, T., H. Kurazono, M. Wille, J. Frevert, K. Wernars, and H. Niemann. 1990. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. *J. Biol. Chem.* 265:9153-9158.
15. Bittner, M. A., B. R. DasGupta, and R. W. Holz. 1989. Isolated light chains of botulinum neurotoxins inhibit exocytosis: studies in digitonin-permeabilized chromaffin cells. *J. Biol. Chem.* 264:10354-10360.
16. Bizzini, B. 1984. Investigation of the mode of action of tetanus toxin with the aid of hybrid molecules consisting in part of tetanus toxin-derived fragments. p. 427-434. *In* J. Jeljaszewicz (ed.), *Bacterial protein toxins*. Academic Press, Inc., New York.
17. Bizzini, B. 1989. Axoplasmic transport and transsynaptic movement of tetanus toxin, p. 203-229. *In* L. L. Simpson (ed.), *Botulinum neurotoxin and tetanus toxin*. Academic Press, Inc., San Diego.
18. Bizzini, B., P. Grab, M. A. Glicksman, and M. Akert. 1980. Use of the B-IIb tetanus-toxin-derived fragment as a specific neuropharmacological transport agent. *Brain Res.* 193:221-227.
19. Bizzini, B., K. Stoekel, and M. Schwab. 1977. An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides and retrograde axonal transport in various neuron systems. *J. Neurochem.* 28:529-542.
20. Black, J. D., and J. O. Dolly. 1986. Interaction of ¹²⁵I-labelled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor mediated endocytosis. *J. Cell Biol.* 103:533-544.
21. Bonventre, P. F., and L. L. Kempe. 1960. Physiology of toxin production by *Clostridium botulinum* types A and B. I. Growth, autolysis, and toxin production. *J. Bacteriol.* 79:18-23.
22. Borison, H. L., L. E. McCarthy, and S. Ellis. 1984. Neurological analysis of respiratory, cardiovascular and neuromuscular effects of brevetoxin in cats. *Toxicol.* 23:517-524.
23. Borodic, G. E., D. Cozzolino, R. Ferrante, A. W. Wiegner, and R. R. Young. 1991. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. *Ophthalmol. Plastic Reconstr. Surg.* 7:54-60.
24. Boradic, G. E., M. Joseph, L. Fay, D. Cozzolino, and R. J. Ferrante. 1990. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. *Head Neck* 12:392-398.
25. Borodic, G. E., L. B. Pearce, E. A. Johnson, and E. J. Schantz. 1991. Clinical and scientific aspects of botulinum A toxin. *Ophthalmol. Clin. North Am.* 4:491-501.
26. Borodic, G. E., L. B. Pearce, K. L. Smith, M. Phelan, and R. Ferrante. Submitted for publication.
27. Boroff, D. A. 1955. Study of toxins of *Clostridium botulinum*. III. Relation of autolysis to toxin production. *J. Bacteriol.* 70:363-367.
28. Bowers, L. E., and O. B. Williams. 1963. Effect of arginine on growth and lysis of *Clostridium botulinum*. *J. Bacteriol.* 85:1175-1176.
29. Brooks, V. B. 1954. The action of botulinum toxin on motor-nerve filaments. *J. Physiol.* 123:501-515.
30. Broquist, H. P., and J. J. Snyder. 1971. *Rhizoctonia* toxin, p. 319-333. *In* S. Kadis, A. Cieglar, and S. J. Ajl (ed.), *Microbial toxins. A comprehensive treatise*, vol. VII. Algal and fungal toxins. Academic Press, Inc., New York.
31. Browne Goode, G., and D. L. Shearn. 1982. Botulism. A case associated with sensory abnormalities. *Arch. Neurol.* 39:55.
32. Buehler, H. J., E. J. Schantz, and C. Lamanna. 1947. The elemental and amino acid composition of *Clostridium botulinum* A toxin. *J. Biol. Chem.* 169:295-302.
33. Burgen, A. S. V., F. Dickens, and L. J. Zatman. 1949. The action of botulinum toxin on the neuromuscular junction. *J. Physiol.* 109:10-24.
34. Cain, H. D., and F. G. Falco. 1962. Recurrent tetanus. *Calif. Med.* 97:31-33.
35. Carmichael, W. W. 1988. Freshwater cyanobacteria (blue-green algae) toxins, p. 3-16. *In* C. L. Ownby and G. V. Odell (ed.), *Natural toxins. Characterization, pharmacology and therapeutics*. Pergamon Press, Oxford.
36. Catterall, W. A. 1980. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. *Annu. Rev. Pharmacol.* 20:15-43.
37. Center for Disease Control. 1979. Botulism in the United States, 1899-1977. Handbook for epidemiologists, clinicians, and laboratory workers. Center for Disease Control, Atlanta.
38. Cherington, M. 1974. Botulism: ten-year experience. *Arch. Neurol.* 30:432-437.
39. Cherington, M., and D. W. Ryan. 1968. Botulism and guanidine. *N. Engl. J. Med.* 278:931-933.
40. Chiu, W., D. Rankert, M. A. Cumming, and J. P. Robinson. 1982. Characterization of crystalline filtrate tetanus toxin. *J. Ultrastruct. Res.* 79:285-293.
41. Chu, F. S. 1977. Mode of action of mycotoxins and related compounds. *Adv. Appl. Microbiol.* 22:83-143.
42. Cornblath, D. R., J. T. Stakky, and A. J. Sumner. 1983. Clinical electrophysiology of infantile botulism. *Muscle Nerve* 6:448-452.
43. Cruz-Martinez, A., B. Anciones, M. T. Ferrer, D. Tejedor, M. C. Perez Conde, and E. Becansua. 1985. Electrophysiologic study in benign botulism. *Muscle Nerve* 8:580-585.
44. DasGupta, B. R. 1980. Electrophoretic analysis of *Clostridium botulinum* types A and B hemagglutinins. *Can. J. Microbiol.* 26:992-997.
45. DasGupta, B. R. 1990. Structure and biological activity of botulinum neurotoxin. *J. Physiol. (Paris)* 84:220-228.
46. DasGupta, B. R., and D. A. Boroff. 1968. Separation of toxin and hemagglutinin from crystalline toxin of *Clostridium botulinum* type A by anion exchange chromatography and determination of their dimensions by gel filtration. *J. Biol. Chem.* 243:1065-1072.
47. DasGupta, B. R., and M. L. Dekleva. 1990. Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and around the nicking site. *Biochimie* 72:661-664.
48. DasGupta, B. R., and H. Sugiyama. 1972. Role of a protease in natural activation of *Clostridium botulinum* neurotoxin. *Infect. Immun.* 6:587-590.
49. De Paiva, A., and J. O. Dolly. 1990. Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. *FEBS Lett.* 277:171-174.
50. Dickson, E. C., and E. Shevsky. 1923. Botulism. Studies on the manner in which the toxin of *Clostridium botulinum* acts on the

- body. II. The effect on the voluntary nervous system. *J. Exp. Med.* 38:327-346.
51. Do, H. K., K. Kogure, and U. Simidu. 1990. Identification of deep-sediment bacteria which produce tetrodotoxin. *Appl. Environ. Microbiol.* 56:1162-1163.
 52. Donadio, J. A., E. J. Gangarosa, and G. A. Faich. 1971. Diagnosis and treatment of botulism. *J. Infect. Dis.* 124:108-111.
 53. Drachman, D. B. 1971. Botulinum toxin as a tool for research on the nervous system, p. 325-347. In L. L. Simpson (ed.), *Neuropoisons. Their pathological actions*, vol. 1. Poisons of animal origin. Plenum Press, New York.
 54. Dreyer, F. 1989. Peripheral actions of tetanus toxin, p. 179-202. In L. L. Simpson (ed.), *Botulinum neurotoxin and tetanus toxin*. Academic Press, Inc., San Diego.
 55. Dreyer, F., and A. Schmitt. 1981. Different effects of botulinum A toxin and tetanus toxin on the transmitter releasing process at the mammalian neuromuscular junction. *Neurosci. Lett.* 26:307-311.
 56. Duchen, L. W. 1970. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. *J. Neurol. Neurosurg. Psychiatry* 33:40-54.
 57. Duchen, L. W. 1972. Motor nerve growth induced by botulinum toxin as a regenerative phenomenon. *Proc. R. Soc. Med.* 65:196-197.
 58. Duda, J. J., and J. M. Slack. 1969. Toxin production in *Clostridium botulinum* as demonstrated by electron microscopy. *J. Bacteriol.* 97:900-904.
 59. Duff, J. T., G. G. Wright, J. Klerer, D. E. Moore, and R. H. Bibler. 1957. Studies on immunity to toxins of *Clostridium botulinum*. I. A simplified procedure for isolation of type A toxin. *J. Bacteriol.* 73:42-47.
 60. Edmunds, C. W., and P. H. Long. 1923. Contribution to the pathologic physiology of botulism. *JAMA* 81:542-547.
 61. Eisel, U., W. Jarausch, K. Goretzki, A. Henschen, J. Engels, U. Wellwe, M. Hudel, E. Habermann, and H. Niemann. 1986. Tetanus toxin: primary structure, expression in *E. coli*, and homology with botulinum toxins. *EMBO J.* 5:2495-2502.
 62. Evans, D. M., R. S. Williams, C. C. Shone, P. Hambleton, J. Melling, and J. O. Dolly. 1986. Botulinum neurotoxin B: its purification, radioiodination and interaction with rat brain synaptosomal membranes. *Eur. J. Biochem.* 154:409-416.
 63. Evans, M. H. 1972. Tetrodotoxin, saxitoxin, and related substances: their applications in neurobiology. *Int. Rev. Neurobiol.* 15:83-166.
 64. Fahn, S., C. D. Marsden, and D. B. Calne. 1987. Classification and investigation of dystonia, p. 332-358. In C. D. Marsden and S. Fahn (ed.), *Movement disorders 2*. Butterworths, London.
 65. Fairweather, N. F., and V. A. Lyness. 1986. The complete amino acid sequence of tetanus toxin. *Nucleic Acids Res.* 14:7809-7812.
 66. Fairweather, N. F., V. A. Lyness, D. J. Pickard, G. Allen, and R. O. Thompson. 1986. Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in *Escherichia coli*. *J. Bacteriol.* 165:21-27.
 67. Feeney, R. E., J. H. Mueller, and P. A. Miller. 1944. Growth requirements of *Clostridium tetani*. II. Factors exhausted by growth of the organism. *J. Bacteriol.* 46:559-562.
 68. Fildes, P. 1925. Tetanus: agglutination and toxicity of *B. tetani*. *Br. J. Exp. Pathol.* 6:91-98.
 69. Finn, C. W., R. P. Silver, W. H. Habig, M. C. Hardegree, G. Zon, and C. F. Garon. 1984. The structural gene for tetanus toxin is on a plasmid. *Science* 224:881-884.
 70. Frankovich, T. L., and S. S. Arnon. 1991. Clinical trial of botulism immune globulin for infant botulism. *West. J. Med.* 154:103.
 71. Fujii, N., D. Kimura, T. Yashiki, T. Indoh, T. Murakami, K. Tsuzuki, N. Yokosawa, and K. Oguma. 1991. Cloning of a DNA fragment encoding the 5'-terminus of the botulinum type E toxin gene from *Clostridium butyricum* strain BL6340. *J. Gen. Microbiol.* 137:519-525.
 72. Fujii, N., K. Kimura, T. Murakami, T. Indoh, T. Yashiki, K. Tsuzuki, N. Yokosawa, and K. Oguma. 1990. The nucleotide and deduced amino acid sequences of *EcoRI* fragment containing the 5'-terminal region of *Clostridium botulinum* type E toxin gene cloned from Mashike, Iwanai, and Otaru strains. *Microbiol. Immunol.* 34:1041-1047.
 73. Galazka, A., D. Rymkiewicz, and J. Aleksandrowicz. 1976. Botulinum antitoxins and bacterial IgM and IgG antibodies in sera of persons immunized with botulinum polytoxoid combined with cholera vaccine. I. Response to botulinum toxoid. *Arch. Immunol. Ther. Exp.* 24:631-639.
 74. Gansel, M., R. Penner, and F. Dreyer. 1987. Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor terminals. *Pflügers Arch. Eur. J. Physiol.* 409:404-416.
 75. Gelb, D. J., D. H. Lowenstein, and M. J. Aminoff. 1989. Controlled trial of botulinum injections for the treatment of spasmodic torticollis. *Neurology* 40:1213-1218.
 76. Gill, D. M. 1982. Bacterial toxins: a table of lethal amounts. *Microbiol. Rev.* 46:86-94.
 77. Grez, N., C. A. Lin, W. L. So, and L. R. Sehgal. 1967. The nature of heat resistant toxin in spores of *Clostridium botulinum*. *Jpn. J. Microbiol.* 11:384-394.
 78. Green, J., H. Spear, and R. R. Brinson. 1983. Human botulism (type F)—a rare type. *Am. J. Med.* 75:893-895.
 79. Guyton, A. C., and M. A. McDonald. 1947. Physiology of botulinus toxin. *Arch. Neurol. Psychiatry (Chicago)* 57:578-592.
 80. Habermann, E., and S. Bernath. 1975. Preparation, measurement, and possible use of human antitoxin against *Cl. botulinum* A, B, and E toxins. *Med. Microbiol. Immunol.* 161:203-210.
 81. Habermann, E., and F. Dreyer. 1986. Clostridial neurotoxins: handling and action at the cellular and molecular level. *Curr. Top. Microbiol. Immunol.* 129:93-176.
 82. Habermann, E., F. Dreyer, and H. Bigalke. 1980. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 311:33-40.
 83. Halpern, J. L., W. H. Habig, E. A. Neale, and S. Stibitz. 1990. Cloning and expression of functional fragment C of tetanus toxin. *Infect. Immun.* 58:1004-1009.
 84. Halpern, J. L., L. A. Smith, K. B. Seamon, K. A. Groover, and W. H. Habig. 1989. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. *Infect. Immun.* 57:18-22.
 85. Hara, T., M. Matsuda, and M. Yoneda. 1977. Isolation and some properties of nontoxic derivatives of a strain of *Clostridium tetani*. *Biken J.* 20:105-115.
 86. Hatheway, C. L. 1989. Bacterial sources of clostridial neurotoxins, p. 3-24. In L. L. Simpson (ed.), *Botulinum neurotoxin and tetanus toxin*. Academic Press, Inc., San Diego.
 87. Hauser, D., M. W. Eklund, H. Kurazono, T. Binz, H. Niemann, D. M. Gill, P. Boquet, and M. R. Popoff. 1990. Nucleotide sequence of *Clostridium botulinum* C₁ neurotoxin. *Nucleic Acids Res.* 18:4924.
 88. Helting, T. B., S. Parschat, and H. Engelhardt. 1979. Structure of tetanus toxin: demonstration and separation of a specific enzyme converting intracellular tetanus toxin to the extracellular form. *J. Biol. Chem.* 254:10728-10733.
 89. Helting, T. B., and O. Zwister. 1977. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. *J. Biol. Chem.* 252:187-193.
 90. Henderson, R., J. M. Ritchie, and G. R. Strichartz. 1973. The binding of labelled saxitoxin to sodium channel in nerve membranes. *J. Physiol. (London)* 227:95-126.
 91. Herrero, B. A., A. E. Ecklund, C. S. Street, et al. 1967. Experimental botulism in monkeys—a clinical pathological study. *Exp. Mol. Pathol.* 6:84-95.
 92. Hertz, E. 1944. Dystonia. I. Historical review: analysis of dystonic symptoms and physiologic mechanisms involved. *Arch. Neurol. Psychiatry* 51:305-318.
 93. Hille, B. 1971. The permeability of the sodium channel to

- organic cations in myelinated nerve. *J. Gen. Physiol.* 58:599-619.
94. Hoch, D. H., M. Romero-Mira, B. E. Ehrlich, A. Finkelstein, B. R. DasGupta, and L. L. Simpson. 1985. Channels formed by botulinum, tetanus and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes. *Proc. Natl. Acad. Sci. USA* 82:1692-1696.
 95. Hughes, J. M., J. R. Blumenthal, M. H. Merson, G. L. Lombard, V. R. Dowell, and E. J. Gangarosa. 1981. Clinical features of types A and B food-borne botulism. *Ann. Intern. Med.* 95:442-445.
 96. Huhtanen, C. 1991. Non-toxic dissociants of *Clostridium botulinum* types A and B, p. 274, abstr. P44. Abstr. 91st Gen. Meet. Am. Soc. Microbiol. 1991. American Society for Microbiology, Washington, D.C.
 97. Jackim, E., and J. Gentil. 1968. Toxins of a blue-green alga: similarity to saxitoxin. *Science* 162:915-916.
 98. Jankovic, J., and M. F. Brin. 1991. Therapeutic uses of botulinum toxin. *N. Engl. J. Med.* 324:1186-1194.
 99. Jankovic, J., and K. Schwartz. 1991. Botulinum toxin treatment of tremors. *Neurology* 41:1185-1188.
 100. Jenzer, G., M. Mumenthaler, H. P. Ludin, and F. Robert. 1975. Autonomic dysfunction in botulism B: a clinical report. *Neurology* 25:150-153.
 - 100a. Jones, S., L. Haugh, F. Starer, Z. Huma, Y. Young, and L. Sinclair. 1990. Central nervous system involvement in infantile botulism. *Lancet* 335(8683):228.
 101. Johnson, E. A., M. C. Goodnough, and E. J. Schantz. Unpublished data.
 102. Kao, C. Y., and S. R. Levison (ed.). Tetrodotoxin, saxitoxin, and the molecular biology of the sodium channel. *Ann. N.Y. Acad. Sci.* 479:1-448.
 103. Kao, C. Y., and A. Nishiyama. 1965. Actions of saxitoxin on peripheral neuromuscular systems. *J. Physiol. (London)* 180: 50-66.
 104. Kaufman, J. A., J. F. Way, L. S. Siegel, and L. C. Sellin. 1985. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. *Toxicol. Appl. Pharmacol.* 79:211-217.
 105. Kimura, K., N. Fujii, K. Tsuzuki, T. Murakami, T. Indoh, N. Yokosawa, and K. Oguma. 1991. Cloning of the structural gene for *Clostridium botulinum* type C₁ toxin and whole nucleotide sequence of its light-chain component. *Appl. Environ. Microbiol.* 57:1168-1172.
 106. Kimura, K., N. Fujii, K. Tsuzuki, T. Murakami, T. Indoh, N. Yokosawa, K. Takeshi, B. Syuto, and K. Oguma. 1990. The complete nucleotide sequence of the gene coding for botulinum type C₁ toxin in the C-ST genome. *Biochem. Biophys. Res. Commun.* 171:1304-1311.
 107. Kinder, S. H., and J. Mager. 1956. Toxin production by *C. parbotulinum* type A. *J. Gen. Microbiol.* 15:394-403.
 108. Koenig, M. G., D. J. Drutz, A. J. Mushlin, W. Schaffner, and D. E. Rogers. 1967. Type B botulism in man. *Am. J. Med.* 42:208-219.
 109. Koenig, M. G., A. Spickard, M. A. Cardella, and D. E. Rogers. 1964. Clinical and laboratory observations on type E botulism in man. *Medicine* 43:517-545.
 110. Kozaki, S. 1979. Interaction of botulinum type A, B, and E derivative toxins with synaptosomes of rat brain. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 308:67-70.
 111. Kozaki, S., S. Sugii, I. Ohishi, S. Sakaguchi, and G. Sakaguchi. 1975. *Clostridium botulinum* type A, B, E, and F 12S toxins. *Jpn. J. Med. Sci. Biol.* 28:70-72.
 112. Laird, W. J., W. Aaronsen, R. P. Silver, W. H. Habig, and M. C. Hardegree. 1980. Plasmid-associated toxigenicity in *Clostridium tetani*. *J. Infect. Dis.* 142:623.
 113. Lamanna, C., H. W. Eklund, and O. E. McElroy. 1946. Botulinum toxin (type A): including a study of shaking with chloroform as a step in the isolation procedure. *J. Bacteriol.* 52:1-13.
 114. Lamanna, C., N. El-Hage, and J. A. Vick. 1988. Cardiac effects of botulinum toxin. *Arch. Int. Pharmacodyn.* 293:69-83.
 115. Lamanna, C., and J. P. Lowenthal. 1951. The lack of identity between hemagglutinin and the toxin type A botulinum organism. *J. Bacteriol.* 61:751-752.
 116. Lange, D. J., M. Rubin, P. E. Greene, U. J. Kand, C. B. Moskowitz, M. F. Brin, R. E. Lovelace, and S. Fahn. 1991. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. *Muscle Nerve* 14:672-675.
 117. Latham, W. C., D. F. Bent, and L. Levine. 1962. Tetanus toxin production in the absence of protein. *Appl. Microbiol.* 10:146-152.
 118. Lewis, K. H., and E. V. Hill. 1947. Practical media and control measures for producing highly toxic cultures of *Clostridium botulinum* type A. *J. Bacteriol.* 53:213-230.
 119. Leyer, G. J., and E. A. Johnson. 1990. Repression of toxin production by tryptophan in *Clostridium botulinum* type E. *Arch. Microbiol.* 154:443-447.
 120. Lomneth, R., T. F. J. Martin, and B. R. DasGupta. 1991. Botulinum neurotoxin light chain inhibits norepinephrine secretion in PC12 cells at an intracellular membranous or cytoskeletal site. *J. Neurochem.* 57:1413-1421.
 121. Magasanik, B. Personal communication.
 122. Mahmood, N. A., and W. W. Carmichael. 1986. Paralytic shellfish poisons produced by the freshwater cyanobacterium *Aphanizomenon flos-aquae* NH-5. *Toxicon* 24:175-186.
 123. Maisey, E. A., D. F. Wadsworth, B. Poulain, C. C. Shone, J. Melling, P. Gibbs, L. Tauc, and J. O. Dolly. 1988. Involvement of constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. *Eur. J. Biochem.* 177: 683-691.
 124. Makoff, A. J., S. P. Ballantine, A. E. Smallwood, and N. F. Fairweather. 1989. Expression of tetanus toxin fragment C in *E. coli*: its purification and potential use as a vaccine. *Bio/Technology* 7:1043-1046.
 125. Makoff, A. J., M. D. Oxer, M. A. Romanos, N. F. Fairweather, and S. Ballantine. 1989. Expression of tetanus toxin fragment C in *E. coli*: high level expression by removing rare codons. *Nucleic Acids Res.* 17:10191-10202.
 126. Malizio, C., and H. Sugiyama. Personal communication.
 127. Marsden, C. D., and N. P. Quinn. 1990. The dystonias. Neurological disorders affecting 20,000 people in Britain. *Br. Med. J.* 300:139-144.
 128. Marxen, P., G. Erdmann, and H. Bigalke. 1991. The translocation of botulinum A neurotoxin by chromaffin cells is promoted in low ionic strength solution and is insensitive to trypsin. *Toxicon* 29:181-189.
 129. Matsuda, M. 1989. The structure of tetanus toxin, p. 69-92. In L. L. Simpson (ed.), *Botulinum toxin and neurotoxin*. Academic Press, Inc., San Diego.
 130. Matsuda, M., N. Sugimoto, K. Ozutsumi, and T. Hirai. 1982. Acute botulinum-like intoxication by tetanus neurotoxin in mice. *Biochem. Biophys. Res. Commun.* 104:799-805.
 131. Mellanby, J. 1968. The effect of glutamate on toxin production by *Clostridium tetani*. *J. Gen. Microbiol.* 54:77-82.
 132. Mellanby, J. 1984. Comparative activities of tetanus and botulinum toxins. *Neuroscience* 11:29-34.
 133. Melling, J., P. Hambleton, and C. C. Shone. 1988. *Clostridium botulinum* toxins: nature and preparation for clinical use. *Eye* 2:16-23.
 134. Meyer, K. F., and B. Eddie. 1951. Perspectives concerning botulism. *Z. Hyg. Infektionskr.* 135:255-263.
 135. Miyasaki, S., M. Iwasaki, and G. Sakaguchi. 1977. *Clostridium botulinum* type D toxin: purification, molecular structure, and some immunological properties. *Infect. Immun.* 17:395-401.
 136. Mochida, S., B. Poulain, U. Eiselt, T. Binz, H. Kurazono, H. Niemann, and L. Tauc. 1990. Exogenous mRNA encoding tetanus or botulinum neurotoxins expressed in *Aplysia* neurons. *Proc. Natl. Acad. Sci. USA* 87:7844-7848.
 137. Molgo, J., J. X. Comella, D. Angaut-Petit, M. Pecot-Dechavassine, N. Tabit, L. Faillat, A. Mallart, and S. Thesleff. 1990. Presynaptic actions of botulinum neurotoxins at vertebrate neuromuscular junctions. *J. Physiol. (Paris)* 84:152-166.
 138. Montecucco, C., E. Papini, and G. Piton. 1987. Does tetanus toxin have a sequence homology with the haemagglutinin of

- influenza virus? *Toxicon* 25:911-912.
139. Moriishi, K., B. Syuto, S. Kubo, and K. Oguma. 1989. Molecular diversity of neurotoxins from *Clostridium botulinum* type D strains. *Infect. Immun.* 57:2886-2891.
 140. Morton, H. E. 1961. The toxicity of *Clostridium botulinum* type A toxin for various species of animals, including man. Institute for Cooperative Research, University of Pennsylvania, Philadelphia.
 141. Mueller, J. H., and P. A. Miller. 1942. Growth requirements of *Clostridium tetani*. *J. Bacteriol.* 43:763-772.
 142. Mueller, J. H., and P. A. Miller. 1945. Production of tetanal toxin. *J. Immunol.* 50:377-384.
 143. Mueller, J. H., and P. A. Miller. 1948. Unidentified nutrients in tetanus toxin production. *J. Bacteriol.* 56:219-233.
 144. Mueller, J. H., and P. A. Miller. 1956. Essential role of histidine peptides in tetanus toxin production. *J. Biol. Chem.* 223:185-194.
 145. Nishida, S., T. Yamagishi, K. Tamai, I. Sanada, and K. Takahashi. 1969. Effects of heat selection on toxigenicity, cultural properties and antigenic structures of clostridia. *J. Infect. Dis.* 120:507-516.
 146. Nukina, M., T. Miyata, S. Sakaguchi, and G. Sakaguchi. 1991. Detection of neutral sugars in purified type G botulinum progenitor toxin and the effects of some glycolytic enzymes on its molecular dissociation and oral toxicity. *FEMS Microbiol. Lett.* 79:159-164.
 147. Nutt, J. G., M. D. Muentner, A. Aronson, L. T. Kurland, and L. J. Melton. 1988. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. *Movement Disorders* 3:188-194.
 148. Oguma, K., H. Iida, and M. Shiozaki. 1976. Phage conversion to hemagglutinin in *Clostridium botulinum* types C and D. *Infect. Immun.* 14:597-602.
 149. Oguma, K., S. Murayama, B. Syuto, H. Iida, and S. Kubo. 1984. Analysis of antigenicity of *Clostridium botulinum* type C, and D toxins by polyclonal and monoclonal antibodies. *Infect. Immun.* 43:584-588.
 150. Ohishi, I. 1984. Oral toxicities of *Clostridium botulinum* type A and B toxins from different strains. *Infect. Immun.* 43:487-490.
 151. Oppenheim, H. 1911. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dysbasia lordotica progressiva, spondylia musculorum deformans). *Neurol. Zentralbl.* 30:1090-1107.
 152. Patterson-Curtis, S., and E. A. Johnson. 1989. Regulation of neurotoxin and protease formation in *Clostridium botulinum* Okra B and Hall A by arginine. *Appl. Environ. Microbiol.* 55:1544-1548.
 153. Pavlova, I. B., and T. I. Sergeeva. 1969. Ultrastructure of toxigenic and nontoxigenic strains of *Cl. tetani*. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 46:12-15.
 154. Perkins, W. F., and K. Tsuji. 1962. Sporulation of *Clostridium botulinum*. II. Effect of arginine and its degradation products on sporulation in synthetic medium. *J. Bacteriol.* 84:86-94.
 155. Pestronk, A., and D. B. Drachman. 1978. Motor nerve sprouting and acetylcholine receptors. *Science* 199:1223-1225.
 156. Pillemmer, L., R. G. Wittler, J. I. Burrell, and D. B. Grossberg. 1948. The immunochemistry of toxins and toxoids. IV. The crystallization and characterization of tetanal toxin. *J. Exp. Med.* 88:205-221.
 157. Popoff, M., P. Boquet, D. M. Gill, and M. W. Eklund. 1990. DNA sequence of exoenzyme C₃ and ADP-ribosyltransferase encoded by *Clostridium botulinum* C and D phages. *Nucleic Acids Res.* 18:1291.
 158. Poulain, B., S. Mochida, J. D. F. Wadsworth, U. Weller, E. Habermann, J. O. Dolly, and L. Taue. 1990. Inhibition of neurotransmitter release by botulinum neurotoxins and tetanus toxin at *Aplysia* synapses: role of the constituent chains. *J. Physiol. (Paris)* 84:247-261.
 159. Prescott, L. M., and R. A. Altenbern. 1967. Inducible lysis in *Clostridium tetani*. *J. Bacteriol.* 93:1220-1226.
 160. Prescott, L. M., and R. A. Altenbern. 1967. Detection of bacteriophages from two strains of *Clostridium tetani*. *J. Virol.* 1:1085-1086.
 161. Putnam, F. W., C. Lamanna, and D. G. Sharp. 1948. Physicochemical properties of crystalline *Clostridium botulinum* type A toxin. *J. Biol. Chem.* 176:401-412.
 162. Raynaud, M. 1951. Extraction de la toxine tétanique à partir des corps microbiens. *Ann. Inst. Pasteur (Paris)* 80:356-377.
 163. Ritchie, J. M., and R. B. Rogart. 1977. The binding of labelled saxitoxin to the sodium channels in normal and denervated mammalian muscle and in amphibian muscle. *J. Physiol. (London)* 269:341-354.
 164. Ritchie, J. M., and R. B. Rogart. 1977. Density of sodium channel in mammalian myelinated nerve fibers and the nature of the axonal membrane under the myelin sheath. *Proc. Natl. Acad. Sci. USA* 75:218-222.
 165. Robinson, J. P. 1988. Purification of tetanus toxin and its major peptides. *Methods Enzymol.* 165:85-90.
 166. Robinson, J. P., and J. H. Hash. 1982. A review of the molecular structure of tetanus toxin. *Mol. Cell. Biochem.* 48:33-44.
 167. Robinson, J. P., M. F. Schmid, D. G. Morgan, and W. Chiu. 1988. Three-dimensional structural analysis of tetanus toxin by electron crystallography. *J. Mol. Biol.* 200:367-375.
 168. Sakaguchi, G. 1983. *Clostridium botulinum* toxins. *Pharmacol. Ther.* 19:165-194.
 169. Sakaguchi, G., I. Ohishi, and S. Kozaki. 1981. Purification and oral toxicities of *Clostridium botulinum* progenitor toxins. p. 21-34. In G. E. Lewis (ed.), *Biomedical aspects of botulism*. Academic Press, Inc., New York.
 170. Sakaguchi, G., and S. Sakaguchi. 1974. Oral toxicities of *Clostridium botulinum* type E toxins of different forms. *Jpn. J. Med. Sci. Biol.* 27:241-244.
 171. Sathyamoorthy, V., and B. R. DasGupta. 1985. Separation, purification, partial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B, and E. *J. Biol. Chem.* 260:10461-10466.
 172. Schantz, E. J. 1960. Biochemical studies on paralytic shellfish poisons. *Ann. N.Y. Acad. Sci.* 90:843-855.
 173. Schantz, E. J. 1964. Purification and characterization of *C. botulinum* toxins, p. 91-104. In K. H. Lewis and K. Cassel, Jr. (ed.), *Botulism. Proceedings of a symposium*. U.S. Department of Health, Education, and Welfare, Public Health Service, Cincinnati.
 174. Schantz, E. J. 1973. Seafood toxicants. p. 424-447. In F. M. Strong (ed.), *Toxicants occurring naturally in foods*. 2nd ed. National Academy of Sciences, Washington, D.C.
 175. Schantz, E. J., V. E. Ghazarossian, H. K. Schnoes, F. M. Strong, J. P. Springer, J. O. Pezzanite, and J. Clardy. 1975. The structure of saxitoxin. *J. Am. Chem. Soc.* 97:1238-1239.
 176. Schantz, E. J., and E. A. Johnson. 1990. Dose standardisation of botulinum toxin. *Lancet* 335:421.
 177. Schantz, E. J., and D. A. Kautter. 1978. Standardized assay for *Clostridium botulinum* toxins. *J. Assoc. Off. Anal. Chem.* 61:96-99.
 178. Schantz, E. J., and M. A. Lauffer. 1962. Diffusion measurements in agar gel. *Biochemistry* 1:658-663.
 179. Schantz, E. J., J. D. Mold, D. W. Stanger, J. Shavel, F. J. Reil, J. P. Bowden, J. M. Lynch, R. S. Wyler, B. R. Reigel, and H. Sommer. 1957. Paralytic shellfish poison. VI. A procedure for the isolation and purification of the poison from toxic clams and mussel tissues. *J. Am. Chem. Soc.* 79:5230-5235.
 180. Schantz, E. J., and A. B. Scott. 1981. Use of crystalline type A botulinum toxin in medical research. p. 143-150. In G. E. Lewis (ed.), *Biomedical aspects of botulism*. Academic Press, Inc., New York.
 181. Schantz, E. J., and L. Spero. 1967. Molecular size of *Clostridium botulinum* type A toxin. p. 296-301. In M. Ingram and T. A. Roberts (ed.), *Botulism 1966*. Chapman & Hall, Ltd., London.
 182. Schantz, E. J., D. Stefanye, and L. Spero. 1960. Observations of the fluorescence and toxicity of botulinum toxin. *J. Biol. Chem.* 235:3489-3491.
 183. Schantz, E. J., and H. Sugiyama. 1974. Toxic proteins produced by *Clostridium botulinum*. *J. Agric. Food-Chem.* 22:26-30.

262

184. Schengrund, C.-L., B. R. DasGupta, and N. J. Ringler. 1991. Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof. *J. Neurochem.* 57:1024-1032.
185. Scheuer, P. J., W. Takahashi, T. Tsutsumi, and T. Yoshida. 1967. Ciguatoxin: isolation and chemical nature. *Science* 155:1268.
186. Schroeder, K., and A. Tollefsrud. 1962. Botulism from fermented trout. *T. Norske Laegeforen* 82:1084-1087.
187. Scott, A. B. Personal communication.
188. Scott, A. B. 1980. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *Ophthalmology* 87:1044-1049.
189. Scott, A. B. 1981. Botulinum toxin injection of eye muscles to correct strabismus. *Trans. Am. Ophthalmol. Soc.* 79:734-770.
190. Scott, A. B. 1988. Antitoxin reverses botulinum side effects. *Eye* 2:29-32.
191. Scott, A. B. 1989. Clostridial toxins as therapeutic agents. p. 399-412. In L. L. Simpson (ed.), *Botulinum neurotoxin and tetanus toxin*. Academic Press, Inc., San Diego.
192. Scott, A. B., A. Rosenbaum, and C. C. Collins. 1973. Pharmacologic weakening of extraocular muscles. *Invest. Ophthalmol.* 12:924-927.
193. Scott, A. B., and D. Suzuki. 1988. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. *Movement Disorders* 3:333-335.
194. Sellin, L. C., J. A. Kauffman, and B. R. DasGupta. 1983. Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. *Med. Biol.* 61:120-125.
195. Sellin, L. C., S. Thesleff, and B. R. DasGupta. 1983. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. *Acta Physiol. Scand.* 119:127-133.
196. Shone, C. C., P. Hambleton, and J. Melling. 1985. Inactivation of *Clostridium botulinum* type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. *Eur. J. Biochem.* 151:75-82.
197. Siegel, L. S. 1988. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. *J. Clin. Microbiol.* 26:2351-2356.
198. Siegel, L. S., and J. F. Metzger. 1979. Toxin production by *Clostridium botulinum* type A under various fermentation conditions. *Appl. Environ. Microbiol.* 38:606-611.
199. Simidu, U., K. Kita-Tsukamoto, T. Yasumoto, and M. Yotsu. 1990. Taxonomy of four bacterial strains that produce tetrodotoxin. *Int. J. Syst. Bacteriol.* 40:331-336.
200. Simpson, L. L. 1981. The origin, structure, and pharmacological activity of botulinum toxin. *Pharmacol. Rev.* 33:155-188.
201. Simpson, L. L. 1984. Fragment C of tetanus toxin antagonizes the neuromuscular blocking properties of native tetanus toxin. *J. Pharmacol. Exp. Ther.* 228:600-605.
202. Simpson, L. L. 1984. Botulinum toxin and tetanus toxin recognize similar membrane determinants. *Brain Res.* 305:177-180.
203. Snipe, P. T., and H. Sommer. 1928. Studies on botulinus toxin. 3. Acid precipitation of botulinus toxin. *J. Infect. Dis.* 43:152-160.
204. Somers, E., and B. R. DasGupta. 1991. *Clostridium botulinum* types A, B, C1, and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes? *J. Protein Chem.* 10:415-425.
205. Sommer, H., and K. F. Meyer. 1937. Paralytic shellfish poisoning. *Am. Med. Assoc. Arch. Pathol.* 24:560-598.
206. Sommer, H., W. F. Whedon, C. A. Kofoid, and R. Stohler. 1937. Relation of paralytic shellfish poison to certain plankton organisms of the genus *Gonyaulax*. *Am. Med. Assoc. Arch. Pathol.* 24:537-559.
207. Stefanye, D., E. J. Schantz, and L. Spero. 1967. Amino acid composition of crystalline botulinum toxin type A. *J. Bacteriol.* 94:277-278.
208. Stell, R., P. D. Thompson, and C. D. Marsden. 1988. Botulinum toxin in spasmodic torticollis. *J. Neurol. Neurosurg. Psychiatry* 51:920-923.
209. St. Louis, M. E., H. S. Shaun, M. B. Peck, D. Bowering, G. Morgan, J. Blatherwick, S. Banerjee, G. D. M. Kellys, W. A. Black, M. E. Milling, A. H. W. Hasuchild, R. V. Tauxe, and P. A. Blake. 1988. Botulism from chopped garlic: delayed recognition of a major outbreak. *Ann. Intern. Med.* 108:363-368.
210. Sugii, S., I. Ohishi, and G. Sakaguchi. 1977. Correlation between oral toxicities and in vitro stabilities of *Clostridium botulinum* type A and B toxins of different molecular sizes. *Infect. Immun.* 16:910-914.
211. Sugii, S., and G. Sakaguchi. 1975. Molecular construction of *Clostridium botulinum* type A toxins. *Infect. Immun.* 12:1262-1270.
212. Sugii, S., and G. Sakaguchi. 1977. Botulinogenic properties of vegetables with special reference to the molecular size of the toxin in them. *J. Food Saf.* 1:53-65.
213. Sugiyama, H. 1980. *Clostridium botulinum* neurotoxin. *Microbiol. Rev.* 44:419-448.
214. Syuto, B., and S. Kubo. 1981. Separation and characterization of heavy and light chains from *Clostridium botulinum* type C toxin and their reconstitution. *J. Biol. Chem.* 256:3712-3717.
215. Tacket, C. O., and M. A. Rogawski. 1989. Botulism, p. 351-378. In L. L. Simpson (ed.), *Botulinum neurotoxin and tetanus toxin*. Academic Press, Inc., San Diego.
216. Takumi, K., T. Kinouchi, and T. Kawata. 1980. Isolation of nontoxic variants associated with enhanced sporulation and alteration in the cell wall from *Clostridium botulinum* 190L by treatment with detergents. *Microbiol. Immunol.* 24:469-477.
217. Taylor, C. F., P. Britton, and S. van Heyningen. 1983. Similarities in the heavy and light chains of tetanus toxin suggested by their amino acid compositions. *Biochem. J.* 209:897-899.
218. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. 1990. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. *Neurology* 40:1332-1336.
219. Thompson, D. E., J. K. Brehm, J. D. Oultram, T.-J. Swinfield, C. C. Shone, T. Atkinson, J. Melling, and N. P. Minton. 1990. The complete amino acid sequence of the *Clostridium botulinum* type A neurotoxin, deduced by nucleotide sequence of the encoding gene. *Eur. J. Biochem.* 189:73-81.
220. Thuesen, E. V., and D. Kogure. 1989. Bacterial production of tetrodotoxin in four species of *Chaetognatha*. *Biol. Bull.* 176:191-194.
221. Truong, D. D., N. Hermanowicz, and M. Rontal. 1990. Botulinum toxin in treatment of tardive dyskinesic syndrome. *J. Clin. Psychopharmacol.* 10:438-439.
222. Tse, C. K., J. O. Dolly, P. Hambleton, D. Wray, and J. Melling. 1982. Preparation and characterization of homogeneous neurotoxin type A from *Clostridium botulinum*. *Eur. J. Biochem.* 122:493-500.
223. Tsunashima, J., K. Sato, K. Shoji, M. Yoneda, and T. Amano. 1964. Excess supplementation of certain amino acids to medium and its inhibitory effect on toxin production by *Clostridium tetani*. *Biken J.* 7:161-163.
224. Tsuzuki, K., K. Kimura, N. Fujii, N. Yokosawa, T. Indoh, T. Murakami, and K. Oguma. 1990. Cloning and complete nucleotide sequence of the gene for the main component of hemagglutinin produced by *Clostridium botulinum* type C. *Infect. Immun.* 58:3173-3177.
225. Tsuzuki, K., N. Yokosawa, B. Syuto, I. Ohishi, N. Fujii, K. Kimura, and K. Oguma. 1988. Establishment of a monoclonal antibody recognizing an antigenic site common to *Clostridium botulinum* types B, C1, D, and E toxins and tetanus toxin. *Infect. Immun.* 56:898-902.
226. van Ermengen, E. 1979. A new anaerobic bacillus and its relation to botulism. *Rev. Infect. Dis.* 1:701-719.
227. Volk, W. A., B. Bizzini, R. M. Snyder, E. Bernhard, and R. R. Wagner. 1984. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. *Infect. Immun.* 45:604-609.
228. Wadsworth, J. D. F., M. Desai, H. S. Tranter, H. J. King, P. Hambleton, J. Melling, J. O. Dolly, and C. C. Shone. 1990.

264
1001

- Botulinum type F neurotoxin. Large-scale purification and characterization of its binding to rat cerebrocortical synaptosomes. *Biochem. J.* 268:123-128.
229. Wagman, J., and J. B. Bateman. 1953. Botulinum type A toxin: properties of a toxic dissociation product. *Arch. Biochem. Biophys.* 45:375-383.
230. Weller, U., M.-E. Dauzenroth, M. Gansel, and F. Dreyer. 1991. Cooperative action of the light chain of tetanus toxin and the heavy chain of botulinum toxin type A on the transmitter release of mammalian motor endplates. *Neurosci. Lett.* 122: 132-134.
231. Weller, U., F. Mauler, and E. Habermann. 1988. Tetanus toxin: biochemical and pharmacological comparison between its protoxin and some isotoxins obtained by limited proteolysis. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 338:99-106.
232. Whitaker, J. R. 1972. Quantitation of purification steps. p. 113. *In* Principles of enzymology for the food sciences. Marcel Dekker, Inc., New York.
233. Williams, R. S., C. K. Tse, J. O. Dolly, P. Hambleton, and J. Melling. 1983. Radioiodination of botulinum neurotoxin A with retention of biological activity and its binding to brain synaptosomes. *Eur. J. Biochem.* 131:437-445.
234. Yasumoto, T., H. Nagai, D. Yasumura, T. Michishita, A. Endo, M. Yotsu, and Y. Kotaki. 1986. Interspecies distribution and possible origin of tetrodotoxin. *Ann. N.Y. Acad. Sci.* 479:44-51.
235. Yotsu, M., T. Yamazaki, Y. Meguro, A. Endo, M. Murata, H. Naoki, and Y. Tasumoto. 1987. Production of tetrodotoxin and its derivatives by *Pseudomonas* sp. isolated from the skin of a pufferfish. *Toxicon* 25:225-228.

05/07524

Antennapedia and HIV Transactivator of Transcription (TAT) “Protein Transduction Domains” Promote Endocytosis of High Molecular Weight Cargo upon Binding to Cell Surface Glycosaminoglycans^{*[S]}

Received for publication, February 19, 2003, and in revised form, June 26, 2003
Published, JBC Papers in Press, June 30, 2003, DOI 10.1074/jbc.M301726200

Sandra Console†§, Cornelia Marty†§, Carlos García-Echeverría†, Reto Schwendenert†,
and Kurt Ballmer-Hofer†||

From ‡Biomolecular Research, Paul Scherrer Institut, CH-5232 Villigen, Switzerland and §Oncology Research,
Novartis Pharma Inc., CH-4002 Basel, Switzerland

Protein transduction domains (PTDs) are short basic peptide sequences present in many cellular and viral proteins that mediate translocation across cellular membranes. PTDs have become widely used as tools for the delivery of high M_r polypeptides, polynucleotides, or nanoparticles to cells in culture; and even the transfer of cargo molecules to the tissue of live animals has been reported. These cell-permeable peptides are functional when fused in-frame to recombinant polypeptides or when chemically coupled to their cargo. The mechanism responsible for PTD-mediated membrane translocation is controversially discussed and may vary among the various PTDs reported in the literature. Thus direct physical interaction with membrane lipids resulting in vectorial delivery to cells has been proposed for the Antennapedia (Antp) PTD, whereas uptake by the retroviral TAT (transactivator of transcription) protein PTD seems to require cell surface-expressed glycosaminoglycans. The view that PTD-mediated cellular uptake is energy-independent has been dismissed recently as an artifact resulting from fixation of cells. The data reported here agree with and further extend this work. They support the idea that certain PTDs promote cellular uptake via endocytosis and require the expression of negatively charged glycosaminoglycans on the surface of the target cells. Uptake of Antp PTD conjugates or peptide-derivatized liposomes was blocked by heparan sulfate proteoglycans, whereas TAT-mediated uptake was inhibited by both heparin and dextran sulfate. Mutant cells defective for glycosaminoglycan synthesis showed dramatically reduced Antp- or TAT-mediated transmembrane transport confirming the role of these complex polysaccharides in PTD-mediated cellular uptake. The fact that PTDs selectively interact with distinct glycosaminoglycan species has implications for therapeutic applications and may allow targeting of selective tissues that differ in their surface-expressed glycosaminoglycan patterns.

^{*} This work was supported by Grant SKL 1220-02-20002 from Schweizerische Krebsliga (to S. C.) and by a grant from Krebsliga Zürich (to C. M.). C. M. was supported by a fellowship from Krebsliga Zürich. S. C. was supported by a fellowship from Krebsliga Schweiz. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. A–C with legends.

§ These two authors contributed equally to this work.

|| To whom correspondence should be addressed. E-mail: kurt.ballmer@psi.ch.

Uptake of charged molecules or high molecular weight compounds into live cells is hampered by the lipophilic nature of the plasma membrane. Thus high amounts of drugs are often required to maintain pharmacologically active concentrations in the target tissue of an organism. The human immunodeficiency virus (HIV)-1-encoded transactivator of transcription (TAT) protein rapidly crosses the plasma membrane of live cells (1, 2). More recently, additional cellular and viral proteins with similar features have been described, such as VP22, a herpesvirus protein involved in regulating transcription, and Antennapedia (Antp) a transcription factor discovered first in insect cells. In all of these proteins, the activity of translocating across cellular membranes is confined to a short stretch of less than 20 amino acids highly enriched in basic residues. These sequences are now called “protein transduction domains” or PTD sequences and act independently from other protein motifs. They have been used both *in vitro* and *in vivo* to target proteins, nucleic acid polymers, or nanoparticles (such as liposomes) to cells (reviewed in Refs. 3–7).

The mechanism responsible for PTD-dependent membrane translocation is controversially discussed and may vary among the various PTDs. In recent papers, it has been proposed that Antp peptide-mediated membrane translocation is an energy-independent process and may be a direct consequence of PTD association with membrane lipids (8, 9). This mechanism would require the formation of transient micelles that are subsequently transferred to the cytoplasmic side of the membrane where cargo molecules are then released. This concept has been questioned in the meantime, and it has been demonstrated that PTD translocation at low temperature is an artifact resulting from the fixation of cells (10, 11). Other data suggest that, at least for the TAT peptide, membrane translocation is mediated by cell surface-expressed heparan sulfate glycosaminoglycans (HPSGs) (12–16). A detailed study of the role of HPSGs in TAT-mediated intracellular transport showed that TAT basic peptide also interferes with the release of newly synthesized HPSGs from cells (17).

Following this line of work, we investigated the uptake mechanism of Antp and TAT PTD protein complexes. The transport to cells by both PTDs occurred only at 37 °C and

¹ The abbreviations used are: HIV, human immunodeficiency virus; Antp, Antennapedia; FITC, fluorescein isothiocyanate; HPSG, heparan sulfate glycosaminoglycan; PBS, phosphate-buffered saline; PTD, protein transduction domain; TAT, transactivator of transcription; TRITC, tetramethylrhodamine isothiocyanate; CHO, Chinese hamster ovary; sulfo-SMCC, 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt.

depended on the expression of negatively charged glycosaminoglycans on the surface of the target cells. PTD complexes associated first with the cell surface and were then rapidly translocated to cytoplasmic vesicles resembling early endosomes. After prolonged exposure of cells at 37 °C, the material accumulated in intracellular vesicular structures. Liposomes tagged with PTD peptides were similarly internalized within the cells thereby improving their potential use for intracellular drug delivery.

EXPERIMENTAL PROCEDURES

Materials—The antibodies for staining lysosomes were G1/139 against human Lamp1 (18) and G1/221 against human transferrin receptor (19). Fluorescent avidin and streptavidin and secondary antibodies were from Southern Biotech (Birmingham, AL). Glycosaminoglycans and dextran sulfate were from Sigma, except for heparin, which was a kind gift from Dr. H. P. Wessel (Hoffman-La Roche). Soybean phosphatidylcholine (SPC) was obtained from L. Meyer (Hamburg, Germany). Cholesterol (Chol) was purchased from Fluka (Buchs, Switzerland), 2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine (DPPE) from Sygens (Liestal, Switzerland), and 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) from Molecular Probes (Leiden, The Netherlands). Sulfo-SMCC was purchased from Pierce (Lausanne, Switzerland).

The mouse melanoma cell line B16F1 was maintained in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum, 1% L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and Nystatin. Wild type CHO K1, CHO pgs A-677, and CHO pgs A-745 cells were from ATCC (Manassas, VA) and were maintained in Ham's F12 medium (20, 21).

Peptide Synthesis—The peptides were synthesized on a Milligen 9050 automated peptide synthesizer (continuous flow), employing the fluorenylmethoxycarbonyl strategy and protocols from our laboratory reported previously (22, 23). After completion of the syntheses, the peptide resins were simultaneously cleaved and deprotected with trifluoroacetic acid/water/ethanedithiol (76:4:20, v/v/v) for 3 h at room temperature, and the crude compounds were purified by reverse-phase medium chromatography on a C18 column (0.1% trifluoroacetic acid/water/acetonitrile gradient). The purity of the peptides was verified by reverse-phase analytical high pressure liquid chromatography, and the identities of the final products were assessed by amino acid and mass spectral analyses (matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF)) analyses. The analytical linear gradient was applied over 2.5 min consisting of acetonitrile, 0.09% trifluoroacetic acid and water, 0.1% trifluoroacetic acid from 1:19 to 3:2 on a Chromolith SpeedROD RP-18e column (50 × 4.6 mm), at a flow rate of 4.0 ml/min; detection at 215 nm; single peak at retention time = 1.45 min (TAT peptide) and retention time = 2 min (Antp peptide). Quantitative amino acid analyses of the peptides revealed the expected amino acid compositions. MALDI-TOF (negative-ion mode) found 2031.5 (calculated 2031.5) for the TAT peptide and 2718.2 (calculated 2718.4) for the Antp peptide.

Internalization of TAT and Antennapedia Peptide Complexes in HeLa Cells—HeLa cells were cultured on coverslips in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Internalization of peptide complexed with either fluorescein isothiocyanate (FITC)-labeled avidin or streptavidin was performed as follows. A 1-µM solution of biotinylated peptide was preincubated with 1 µM fluorescently labeled avidin or streptavidin at room temperature for 30 min with or without inhibitory glycosaminoglycans (50 µg/ml) in Opti-MEM I. Peptide complexes were added to washed HeLa cells on coverslips in Opti-MEM I at 4 °C for 30 min. The cells were fixed in 3.7% formaldehyde or incubated in fresh Opti-MEM I prewarmed to 37 °C for the indicated times to follow protein transduction in the cells. The cells were permeabilized with 0.25% Saponin for 3 min for costaining of internalized FITC-avidin-peptide with antibodies recognizing transferrin (a marker for early endosomes (19)) or Lamp1 (a lysosomal protein (19)). 1% TRITC-labeled dextran was added as a marker for fluid-phase endocytosis in the corresponding assays. The cells were embedded in gelvatol and analyzed on a Zeiss Axiophot fluorescence microscope with epi-illuminescence using a 40× NA 1.4 water immersion lens. Photomicrographs were taken with a Kappa CF 8/1 CCD camera; exposure time was 5 ms for all pictures in the series. Confocal series were acquired with an LSM 410 confocal microscope (Zeiss, Oberkochen, Germany). The Imaris software (Bitplane AG, Zurich, Switzerland) was used for image analysis.

Liposome Preparation and Modification—The liposomes were com-

posed of SPC:Chol:DPPE:DiO at a molar ratio of 1:0.2:0.035:0.004. Small unilamellar liposomes were prepared by sequential filter extrusion of multilamellar liposomal preparations in Soerensen phosphate buffer (SPB, 13 mM KH₂PO₄, 54 mM NaHPO₄, pH 7.4) through Nucleopore membranes (Sterico, Dietikon, Switzerland) of 0.2 µm and 0.1 µm pore diameter with a Lipex extruder (Lipex Biomembranes Inc., Vancouver, British Columbia, Canada). Size and stability of the liposomes were analyzed with a particle sizer (Nicom Model 370, Santa Barbara, CA). For peptide modification, liposomes in SPB were incubated with crystalline sulfo-SMCC at a molar ratio for amino groups to maleimide groups of 1:5 for 30 min at 30 °C. Excess sulfo-SMCC was removed by dialysis overnight at 4 °C against SPB. 3 mg of PTD peptide or cysteine as a control were incubated with 1 ml of sulfo-SMCC-modified liposomes for 20 h at room temperature in 2 mM tributylphosphine under an argon atmosphere. Nonreacted peptide was removed by dialysis against SPB.

Flow Cytometry—Cells (2 × 10⁶ cells in 12-well plates) were grown for 24 h at 37 °C. The medium was removed, and the cells were incubated in serum-free Opti-MEM I for 30 min at 37 °C. Before addition to the cells, PTD-streptavidin complexes or PTD-derivatized liposomes were preincubated with or without 20 µg/ml polysaccharide at room temperature for 15 min. The cells were incubated with the complex in serum-free Opti-MEM I at 37 °C. Complexes were removed, and the cells were cultured in growth medium as described above for 90 min at 37 °C. The cells were washed with PBS (0.137 M NaCl, 2.68 mM KCl, 8.09 mM Na₂HPO₄, 1.76 mM KH₂PO₄, pH 7.4), detached from the plates with 10 mM EDTA in PBS, washed in PBS, and either used directly or after fixation in 3.7% formaldehyde in PBS for flow cytometric analysis. Internalization of PTD complexes or liposomes was determined in a FACScan flow cytometer (BD Biosciences). 10,000 cells were analyzed per data point, and all experiments were carried out in triplicate.

RESULTS

PTD peptide sequences derived from TAT and Antp were SGYGRKKRRRRC and SGRQIKIWFQNRRMKWKKC, respectively. They were both chemically synthesized, biotinylated at the N terminus, and carried a C-terminal cysteine residue for chemical coupling to cargo molecules. The Ser-Gly dipeptide at the N terminus was used as a spacer between the peptide and biotin. These peptides were efficiently delivered to cells and could be detected with FITC-labeled avidin or streptavidin in fixed and permeabilized cells as described earlier (8) (data not shown).

PTD-mediated cellular uptake was next investigated with FITC-labeled avidin or streptavidin conjugated with biotinylated PTD peptide. Intracellular transport of this complex was studied in a variety of cell lines such as HeLa, B16 melanoma, and CHO cells. Complexes were rapidly taken up by all cell types tested. Figs. 1 and 2 show representative data for HeLa cells. FITC-labeled avidin or streptavidin was first preincubated for 15 min with either biotinylated Antp or TAT peptide followed by incubation with cells at 0 °C. The labeled material accumulated in small patches on the surface of the cells (Figs. 1A and 2A). FITC-labeled avidin or streptavidin did not associate with cells in the absence of PTD peptide or when bound to a peptide lacking a PTD domain (Figs. 1O, 2O, and data not shown). This indicates that membrane binding was a specific event mediated by PTD peptide.

Cells incubated with FITC-avidin-peptide complexes were then washed and further incubated at 37 °C in growth medium to induce internalization. As seen in Figs. 1B and 2B, fluorescently labeled material was internalized within minutes and accumulated in vesicular structures resembling early endosomes. These vesicles partially colocalized with TRITC-labeled dextran added during the chase period at 37 °C as a marker for fluid-phase endocytosis (data given in supplemental Fig. A). A marker protein for early endosomes, the transferrin receptor, showed similar localization as avidin-PTD complexes (data given in supplemental Fig. B). After incubation for 1–3 h at 37 °C, the material was confined to intracellular vesicles (Figs. 1C and 2C). Antp complexes showed partial colocalization with




FIG. 1. Cell binding and internalization of FITC-labeled avidin:Antp peptide complexes. Cells were treated with FITC-avidin:Antp complex as described under "Experimental Procedures." A, HeLa cells were incubated for 30 min at 0 °C with PTD complex, washed, and further incubated at 37 °C for 60 min (B) and 180 min (C). O, shows a photomicrograph of cells incubated with FITC-avidin in the absence of peptide. Photomicrographs were taken on a Zeiss Axiophot microscope. D–G, show Z/X- and Z/Y-sections constructed from a confocal series through representative cells. 12 sections of 600–900 nm were taken for each series, and Z-sections were constructed with Imaris software. Z-sections were taken at a line running through the midpoint of the XY plane. D, analysis of a cell treated as in A. E, shows a cells chased for 10 min at 37 °C after PTD binding. F and G, show a similar analysis performed with cells treated for 60 and 180 min at 37 °C, respectively. Bar represents 50 μ m.




FIG. 2. Cell binding and internalization of FITC-labeled avidin:TAT peptide complexes. Treatment and analysis of cells are as described in Fig. 1.

lysosomes (data given in supplemental Fig. B), whereas TAT accumulated in vesicular structures located at the cell periphery (data given in supplemental Fig. C).

To prove that PTD complexes were internalized during the chase period at 37 °C, cells were analyzed by confocal microscopy. Z-sections through cells (Figs. 1 and 2, Z/X and Z/Y) showed that the material was predominantly associated with the extracellular face of the plasma membrane before the chase (Figs. 1D and 2D). Upon extended incubation at 37 °C, both Antp (Fig. 1, F and G) and TAT (Fig. 2, F and G) complexes were transferred to intracellular vesicular structures, whereas after a 10-min chase, most of the material remained on the extracellular surface. Taken together, our data show that both PTDs initially bind to the cell surface in a temperature-independent way where they cluster in small patches on the extracellular side of the plasma membrane. Upon shifting the cells to 37 °C, the material was internalized in intracellular

vesicular structures by a mechanism resembling fluid-phase endocytosis.

We next investigated the mechanism responsible for PTD-mediated cellular uptake. Chinese hamster ovary (CHO) cells were incubated with FITC-labeled streptavidin-PTD complex for 90 min at 37 °C, washed, removed from tissue culture plates with EDTA solution, washed again in PBS, and submitted to flow cytometric analysis. Fig. 3A shows that heparin inhibited association with and internalization of TAT complexes by 60–70%, whereas uptake of streptavidin:Antp complex was reduced by 40–50%. Dextran sulfate inhibited uptake of TAT but not of Antp complexes. Other glycosaminoglycans such as chondroitin sulfate A, B, and C and hyaluronic acid had no effect on PTD-mediated cellular uptake (data not shown). No cellular uptake was observed in controls performed with FITC-labeled streptavidin in the absence of PTD peptide (Fig. 3A). It has recently been shown that fixation of cells promotes artifactual




FIG. 3. A, Antp and TAT/streptavidin complex uptake into CHO cells is inhibited by polysaccharides. CHO cells were incubated for 90 min at 37 °C with FITC-labeled Antp or TAT streptavidin complex in the absence or presence of heparin (Hep) or dextran sulfate (Dex). As a control, cells were treated with FITC-labeled streptavidin alone. Cells were washed, removed from tissue culture plates, fixed, and submitted to flow cytometric analysis. 10,000 cells were analyzed for each data point in triplicate. *Strep*, streptavidin. Error bars show mean $\pm$ S.D. for each triplicate. B, Antp- and TAT-derivatized liposome uptake into B16 cells is inhibited by polysaccharides. B16 melanoma cells were incubated for 90 min at 37 °C with FITC-labeled Antp- or TAT-derivatized liposomes with or without heparin, dextran sulfate, or chondroitin sulfate. Cells were collected and analyzed as in A. C, uptake of PTD complexes into CHO cells. The experiment was performed as in B, and the cells were either directly processed for cytofluorometric analysis or fixed as described under "Experimental Procedures."

association of PTD peptides with cells (10). To rule this out for our experiments, we analyzed cells incubated with PTD complex before and after fixation by flow cytometry. As shown in Fig. 3C, the amount of PTD complex bound to cells and inhibition by heparin was not changed.

Similar experiments were then performed with PTD-derivatized phosphatidylcholine liposomes. The PTD peptides were coupled via a cysteine residue to maleimide derivatized lipids (24). As shown in Fig. 3B, uptake of TAT peptide-modified liposomes was increased 10-fold, whereas Antp-derivatized liposomes were internalized 50 times more efficiently than control liposomes modified with cysteine instead of a PTD peptide. The difference in uptake efficiency presumably results from the fact that TAT-derivatized liposomes tend to form large aggre-

gates that are less well internalized. Uptake of liposomes into CHO cells was blocked by heparin and dextran sulfate but not by other glycosaminoglycans such as chondroitin A (Fig. 3B) or chondroitins B and C and hyaluronic acid (data not shown). Taken together, these data suggest that cell surface-expressed glycosaminoglycans, in particular HPSCs, are required for TAT and Antp PTD-mediated cellular uptake of proteins and liposomes. Dextran sulfate polymers and heparan sulfates inhibited uptake by TAT, whereas Antp-dependent protein uptake was blocked only by heparan sulfates. This suggests differential binding of these peptides to negatively charged extracellular glycosaminoglycans and also indicates that TAT and Antp PTDs rely on different oligosaccharides for initial membrane binding. PTD-derivatized liposome uptake was indiscrimi-




FIG. 4. Antp and TAT-avidin complex uptake into CHO wild type and mutant cells. CHO K1 wild type (pgs A-745 and pgs A-677) mutant cells were incubated for 90 min at 37 °C with FITC-labeled Antp or TAT-streptavidin complex followed by analysis as described for Fig. 3A. Av, FITC-avidin.

nately blocked by inhibitory polysaccharides such as dextran sulfate and heparin.

To corroborate these findings, we investigated PTD uptake into mutant CHO cells deficient in glycosaminoglycan synthesis. Neither Antp nor TAT peptide complexes were efficiently internalized in the mutant cell line (pgs A-745) lacking UDP-D-xylose:serine β -1,3-D-xylosyltransferase (21) (Fig. 4). These cells are deficient in the synthesis of all proteoglycans. A second mutant (pgs A-677) expressing reduced amounts of HPSG because of an $\sim$ 10-fold reduction in *N*-acetylglucosaminyltransferase and glucuronosyltransferase (20) showed a reduction in the uptake of Antp but not of TAT-streptavidin complexes. This suggests that the low amount of HPSG expressed by these cells still allowed PTD-mediated cellular uptake.

DISCUSSION

The data presented here show that the major route for TAT and Antp peptide-mediated cellular uptake of protein molecules and nanoparticles is endocytosis. Uptake by these PTDs was temperature-dependent, indicative of a step requiring energy. The material that initially accumulated on the cell surface in small patches (a process that was temperature-independent) was then followed by internalization in intracellular vesicular structures. The nature of these patches is unclear; they may represent plasma membrane microdomains such as lipid rafts that are enriched in particular membrane proteins carrying, for instance, HPSG polysaccharide chains. The route and kinetics of uptake are similar to those followed by markers for fluid-phase endocytosis such as fluorescent dextran conjugates.

Uptake of avidin- or streptavidin-PTD complexes prepared with either Antp or TAT peptide was blocked by negatively charged high M_r glycosaminoglycans. TAT-mediated binding was blocked by heparan and dextran sulfate, whereas Antp-dependent uptake was blocked only by heparan sulfate. This suggests that the basic character of PTDs promotes their interaction with negatively charged complex sulfated glycosaminoglycans exposed on the surface of cells. Uptake of both Antp and TAT PTD-derivatized liposomes was similarly blocked by

heparin and dextran sulfate. The fact that cells deficient in glycosaminoglycan synthesis showed reduced PTD uptake further supports this notion. Specificity of the various PTDs for different types of glycosaminoglycans may arise from the positive charge distribution in various PTDs; in other words, high affinity interaction with negatively charged sulfated polysaccharides expressed on the cell surface may require proper alignment with the positive charges on a particular PTD. The possibility that PTDs discriminate between different surface-expressed glycosaminoglycans has been discussed earlier for TAT (12–14, 16), and the role that heparan sulfate oligosaccharides play in receptor binding and internalization has also been investigated in other molecules, *e.g.* decorin (25). Finally, Sandgren *et al.* (17) recently published work in which they investigated the role of HPSGs in TAT-mediated cellular uptake in detail. Differential interaction of PTDs with glycosaminoglycans might open new possibilities for the delivery of reagents to specific tissues using more selective PTD sequences. Further optimization of PTD peptides might thus improve their translocation efficiency and may even allow the development of tissue-specific PTDs (26).

The exact localization of cell-associated PTD complexes has not always been critically evaluated in earlier work. We therefore analyzed confocal micrographs such as those shown in Figs. 1 and 2 with an image-processing software. Z-sections of confocal data sets show that fluorescent material initially accumulated in patches on the cell surface, in particular at sites of cell-cell contact. As early as 10 min after shifting cells to a high temperature, fluorescent material appeared in intracellular vesicular structures resembling endosomes. Partial colocalization of PTD complexes with a marker for fluid-phase endocytosis further suggests that uptake is through endocytosis, as proposed earlier (1, 2). 1–2 h after incubation at 37 °C, PTD-cargo complexes accumulated in intracellular vesicular structures. In the case of TAT, these vesicles were localized close to the cell periphery, whereas Antp PTD complexes showed perinuclear staining partially overlapping with a lysosomal marker. The route of cell entry and the turnover of TAT-cargo complexes inside cells have also been investigated in detail recently (17). These authors showed that cellular uptake of TAT-PTD complexes was via endocytosis and that the complexes were subsequently targeted to the nucleus. Together with our data, this suggests that TAT and Antp PTDs target their cargo to different cellular organelles.

Cellular uptake by Antp PTD sequences has not been investigated in detail so far. It has been proposed that Antp peptide directly interacts with membrane lipids (6, 9), a finding that we and others have not been able to confirm (27).² We cannot exclude the possibility, however, that the exact route of cell entry and the transfer to intracellular vesicles may differ for various PTDs. It will be of crucial importance for the further development of PTD technology to dissect these pathways for all PTD sequences, as each PTD might be destined for a specific cellular compartment.

Liposomes are useful for the delivery of fragile reagents that are rapidly degraded in the bloodstream. The drawback is that the release of the liposomal content into target cells is limited by the slow uptake of these vehicles into cells, and little is known about the mechanism of liposome-mediated drug delivery. It is generally assumed that liposomes release their content upon fusion with intracellular membranes. We show here that uptake of PTD-tagged liposomes is dramatically accelerated when compared with control liposomes. This is in agree-

² S. Console, C. Marty, C. Garcia-Echeverria, R. Schwendener, and K. Ballmer-Hofer, unpublished work.


ment with earlier work where similarly modified liposomes have been shown to be efficiently internalized in cells even at low temperature (28). A detailed analysis of the intracellular localization of liposomes was, however, not performed in this study. Based on the data shown here and on recently published work (10), it is possible that liposomes associated with cells at low temperature (as shown in that study) were actually bound to the cell surface rather than being translocated to cells.

In summary, our study extends recently published work (10, 11, 17) and shows that PTD peptides derived from either HIV TAT or Antennapedia promote cellular uptake of cargo through endocytosis. PTD complexes initially accumulate on the surface of target cells and are subsequently translocated across the plasma membrane upon incubation of cells at 37 °C but not at 0 °C. The earlier proposal that PTD peptides penetrate membranes upon direct interaction with the lipid bilayer, although not formally excluded, seems not to apply for uptake of the high M_r cargo molecules used here (Ref. 29, and reviewed in Ref. 6).

Acknowledgments—We thank Dr. H. P. Hauri (Biozentrum Basel) for antibodies, Dr. H. P. Wessel (Hoffmann-La Roche, Basel, Switzerland) for heparin samples, R. Wille for technical assistance, and Dr. J. Jiricny for continuous support of our work.

REFERENCES

- Frankel, A. D., and Pabo, C. O. (1988) *Cell* **55**, 1189–1193
- Mann, D. A., and Frankel, A. D. (1991) *EMBO J.* **10**, 1733–1739
- Fischer, P. M., Krausz, E., and Lane, D. P. (2001) *Bioconjugate Chem.* **12**, 825–841
- Schwarze, S. R., Hruska, K. A., and Dowdy, S. F. (2000) *Trends Cell Biol.* **10**, 290–295
- Schwarze, S. R., and Dowdy, S. F. (2000) *Trends Pharmacol. Sci.* **21**, 45–48
- Derossi, D., Chassaing, G., and Prochiantz, A. (1998) *Trends Cell Biol.* **8**, 84–87
- Lindgren, M., Hallbrink, M., Prochiantz, A., and Langel, U. (2000) *Trends Pharmacol. Sci.* **21**, 99–103
- Vivès, E., Brodin, P., and Lebleu, B. (1997) *J. Biol. Chem.* **272**, 16010–16017
- Derossi, D., Calvet, S., Trembleau, A., Brunissen, A., Chassaing, G., and Prochiantz, A. (1996) *J. Biol. Chem.* **271**, 18188–18193
- Richard, J. P., Melikov, K., Vivès, E., Ramos, C., Verbeure, B., Gait, M. J., Chernomordik, L. V., and Lebleu, B. (2003) *J. Biol. Chem.* **278**, 585–590
- Lundberg, M., and Johansson, M. (2001) *Nature Biotechnol.* **19**, 713–714
- Rusnati, M., Tulipano, G., Urbinati, C., Tanghetti, E., Gialiani, R., Giacca, M., Ciomei, M., Corallini, A., and Presta, M. (1998) *J. Biol. Chem.* **273**, 16027–16037
- Rusnati, M., Tulipano, G., Spillmann, D., Tanghetti, E., Oreste, P., Zoppetti, G., Giacca, M., and Presta, M. (1999) *J. Biol. Chem.* **274**, 28198–28205
- Rusnati, M., Urbinati, C., Caputo, A., Possati, L., Lortat-Jacob, H., Giacca, M., Ribatti, D., and Presta, M. (2001) *J. Biol. Chem.* **276**, 22420–22425
- Suzuki, T., Futaki, S., Niwa, M., Tanaka, S., Ueda, K., and Sugiura, Y. (2002) *J. Biol. Chem.* **277**, 2437–2443
- Tyagi, M., Rusnati, M., Presta, M., and Giacca, M. (2001) *J. Biol. Chem.* **276**, 3254–3261
- Sandgren, S., Cheng, F., and Belting, M. (2002) *J. Biol. Chem.* **277**, 38877–38883
- Schweizer, A., Fransen, J. A., Bachi, T., Ginsel, L., and Hauri, H. P. (1988) *J. Cell Biol.* **107**, 1643–1653
- Vollenweider, F., Kappeler, F., Itin, C., and Hauri, H. P. (1998) *J. Cell Biol.* **142**, 377–389
- Esko, J. D., Stewart, T. B., and Taylor, W. H. (1985) *Proc. Natl. Acad. Sci. U. S. A.* **82**, 3197–3201
- Lidholt, K., Weinke, J. L., Kiser, C. S., Lugenwa, F. N., Bame, K. J., Cheifetz, S., Massague, J., Lindahl, U., and Esko, J. D. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 2267–2271
- García-Echeverría, C. (1996) *Bioorg. Med. Chem. Lett.* **6**, 229–232
- García-Echeverría, C., Stamm, C., Wille, R., Arz, D., and Gay, B. (1997) *Int. Pept. Sci.* **4**, 49–53
- Marty, C., Odarmatt, B., Schott, H., Neri, D., Ballmer-Hofer, K., Klemenz, R., and Schwendener, R. A. (2002) *Br. J. Cancer* **87**, 106–112
- Hausauer, H., and Kresse, H. (1999) *Biochem. J.* **344**, 827–835
- García-Echeverría, C., Jiang, L., Ramsey, T. M., Sharma, S. K., and Chen, Y. P. (2001) *Bioorg. Med. Chem. Lett.* **11**, 1363–1366
- Kramer, S. D., and Wunderli-Allenspach, H. (2003) *Biochim. Biophys. Acta* **1609**, 161–169
- Torchilin, V. P., Rammohan, R., Weissig, V., and Levchenko, T. S. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 8786–8791
- Thoren, P. E., Persson, D., Karlsson, M., and Norden, B. (2000) *FEBS Lett.* **482**, 265–268



Abstract

[Back to Hit List](#)**Grant Number:** 1R43AI043816-01**PI Name:** SHALABY, SHALABY W.**PI Email:** shalaby@poly-med.com**PI Title:****Project Title:** POLYMERS FOR AUGMENTING R BOTULINUM VACCINE EFFICACY

Abstract: DESCRIPTION (Adapted from the applicant's abstract): Botulism is a neuromuscular poisoning caused by clostridial neurotoxins. Humans are exposed to neurotoxins produced by Clostridial botulinum through food poisoning. Incidences of wound botulism and a colonizing infection of neonates known as infant botulism are rare. Although the infective microorganism can be treated by antibiotics, there exists no specific drug therapy for botulinum toxins. Toxoids, as in formalin-inactivated vaccines, can be prepared for active immunization of individuals who are likely to be exposed to C. Botulinum or its toxins. However, problems associated with such immunization, including the need for more than a single dose of expensive, multivalent toxoids, and concerns about reversion of the toxoids to toxins created a need for single-dose immunization with a safe vaccine. Recent availability of recombinant fragment C botulinum (r-FCBt) vaccine and absorbable gel-forming carriers justified pursuing the proposed program. The objective of Phase I is to determine the feasibility of using absorbable gel-forming and micro-spherical polyester carriers in developing a r-FCBt vaccine for intranasal and subcutaneous immunization. Phase I entails (1) preparing and characterizing the polymeric carriers; (2) formulating and evaluating, in mice, candidate controlled release systems using Type E and F r-FCBt vaccines; (3) determining the antibody response; and (4) conducting challenge studies with individual homologous serotypes. Phase I results will be used to design Phase II plans that include (1) studying immunization and protection of all r-FCBt vaccines (A, B, C, D, E, F, and G) against highest dose of homologous and possibly heterologous toxin serotypes; (2) developing, scaling-up, and evaluating a multivalent r-FCBt vaccine; and (3) conducting a brief safety study on the multivalent vaccine. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Thesaurus Terms:

bacterial vaccine, botulinum toxin, nonhuman therapy evaluation, polymer, recombinant protein, vaccine development

Clostridium, microorganism immunology

laboratory mouse, microorganism culture, molecular cloning

Institution: POLY-MED, INC.

6309 HWY 187

ANDERSON, SC 29625

Fiscal Year: 1998**Department:****Project Start:** 30-SEP-1998

272
-52

Project End: 30-SEP-1999

ICD: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

IRG: ZRG5

